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The opiate alkaloid (-)-morphine and the Amaryllidaceae alkaloid (-)-
galanthamine are well known for their analgesic and anticholinergic properties, 
respectively. The chemical feature that connects these two molecules is that they are both 
biosynthesized from an ortho-para phenolic oxidative coupling. Attempts to mimic this 
aesthetic chemistry in the laboratory for the practical production of these alkaloids have 
not resulted in good yields of these compounds and there is a lot of scope for 
improvement. Despite the enormous amount of work devoted to this area, the simple 
para-alkylation of an appropriately substituted phenol derivative to generate a cross 
conjugated 2, 5-cyclohexadienone has not been reported. This strategy would avoid the 
low-yielding phenolic oxidation reaction and the product would merely require a double 
reductive amination of the aromatic aldehyde and the latent aldehyde (in the acetal) to 
produce narwedine, the synthetic precursor to (-)-galanthamine. On the other hand, the 
same intermediate can be elaborated to (±)-morphine via a Henry reaction, followed by 
reduction and reductive amination.  
 vii 
Following the aforementioned methodology, we have successfully completed the 
synthesis of both these alkaloids via the common intermediate, a 2, 5-cross-conjugated 
cyclohexadienone. A demonstration of the use of this methodology towards achieving an 
enantioselective synthesis of these compounds has also been made. The overall yield of 
the 8 step procedure for galanthamine proceeds in 65% yield, which is approximately five 
times the yield of the current manufacturing process for this molecule. The synthesis of 
(±)-morphine, for the first time, allows access to codeine without having to reduce 
codeinone and, with an overall yield of 20% for the 14 step process, makes this the 
shortest synthesis of morphine. 
 viii 
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1.1.1 Historical perspective 
The unripened seeds of the poppy plant, Papaver somniferum, contain a milky 
white fluid which on exposure to air darkens to a thick black paste which has for 
centuries been referred to as opium. Opium has been known for its powerfully analgesic 
and equally euphoric properties since antiquity.1 The first documented evidence of opium 
cultivation comes from the Sumerians in Mesopotamia ca. 3400 BC. As trade between 
the East and West flourished, the knowledge of poppy cultivation, opium production and 
its usage spread eastward to Persia, India and far-east China and westwards as far as 
Spain. Opium became stigmatized in Europe ca. 1300 AD during the inquisitions. 
However, the use of opium for recreational purposes continued in the Islamic and 
Chinese empires. It was only with the return of Paracelsus from Arabia in 1527, that 
opium was reintroduced into Western medicine as Paracelsus’ laudanum.  
By 1729, the use of opium for recreational purposes was so rampant in China that 
the then emperor of the Qing dynasty introduced prohibition on opium usage. The British 
East India Company soon discovered that the illicit trade of opium from India to China 
was a highly profitable venture and illegal trade flourished. Military intervention by the 
Chinese resulted in the First Opium War and ended with the British conquest of Hong 
Kong. Following China’s second defeat in the Second Opium War, the cultivation of 
poppy and the production of opium was legalized in China. Within a span of 50 years, 
 2 
China controlled 85% of the world’s production of opium, but, resulted in a staggering 
27% of the adult population being addicted.  
Following the two World Wars, the global production of opium faced a steady 
decline with the establishment of democracies in most parts of the world and the advent 
of communism in other parts, both of which frowned upon the use of opium. This idea 
was cemented by the United Nations in Article 4 of the Single Convention on Narcotic 
Drugs and all signatory nations agreed “to prohibit the import, sale, distribution, export, 
and use of all narcotic drugs, except for medical and scientific purposes”.2 
 
1.1.2 Medicinal usage 
The English physician Thomas Sydenham (1624–1689) improved upon the recipe 
developed by Paracelsus, and ‘laudanum’ remained a cornerstone of European medicine 
well into the nineteenth century. In 1804, the German scientist Sertürner isolated the first 
active alkaloid extracted from opium and named it ‘morphine’ (1, Figure 1), after 
Morpheus, the Greek god of dreams.3 Diacetylmorphine was synthesized from morphine 
in 18744 and later marketed by Bayer and Co. as ‘heroin’ (2). Heroin was found to be 























Figure 1.01. Morphine and its congeners.  
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Morphine (1) is the principle constituent of the opium extract along with codeine 
(3), and thebaine (4). An average Indian acreage of Papaver somniferum yields between 
25 and 30 kg of opium per season and, after refining, this will afford approximately 3 kg 
of morphine (or 300,000 standard medical units).5 Extraction of opium from P.  
somniferum is a fairly simple process and has remained the same since antiquity. Fifteen 
days after petal fall, the immature seed capsule of the poppy plant is lanced and the fresh 
pink opium latex is collected. A day later, the latex, now black in color, is scraped from 
the capsule and collected. Each capsule is lanced a further three or four times over the 
following week and more opium is collected. The raw opium is partially dehydrated by 
sun baking to remove about 90% of its water content; at this point, the black resinous 
mass, commercially known as Indian opium, contains approximately 10-15% morphine, 
3–4% codeine, 0.1–2% thebaine and 0.5–1% papaverine. 
While in the past morphine was used to treat everything from insomnia to alcohol 
abuse, today morphine forms the bedrock of pain management for patients suffering from 
all moderate to severe pain, including pain associated with HIV/AIDS and cancer. On the 
World Health Organization’s Model List of Essential Medicines, morphine is considered 
the world’s most effective painkiller. 
In the year 2000, an estimated 8700 tons of opium and poppy straw concentrate 
were produced worldwide from over 300,000 hectares of poppy fields. Official figures 
from the International Narcotics Control Board (INCB) show that just six countries 
(USA, UK, France, Canada, Germany and Australia) consume about 80% of this global 
supply, while the developing world, which houses 80% of the world’s population, 
consumes just 5%.6 This vast disparity is a direct result of the affordability. Naturally the 
quest for a genuinely practical synthesis of the opiates, one that can compete with the 
scale of natural supply and price, continues to attract the attention of scientists.  
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1.1.3 Isolation and Characterization 
Investigation into the structure of the alkaloid began soon after its initial isolation. 
Early studies by Liebig were followed by those of Laurent,7 who correctly deduced the 
empirical formula of morphine as C17H19NO3 in 1847. The diacetylation to heroin by 
Wright proved the presence of two hydroxyl groups.4 Grimaux demonstrated that a facile 
monomethylation implied the phenolic nature of one of them.8 The oxidation of codeine 
to codeinone established the secondary nature of the other hydroxyl, leading to the 
assumption that the third oxygen must be an unreactive ether linkage. Hydrogenation 
established the presence of a double bond and monobromination validated the presence of 
the aromatic ring. Von Braun degradation (NMe → NCN) and Hoffman degradation 
meant there was a cyclic tertiary amine, and exhaustive Hoffman degradation to produce 
trimethylamine, ethylene and an aromatic compound, suggested a phenethylamine-type 
skeleton with a bridged ethylamine linkage. Distillation from zinc dust produced various 
oxygenated phenanthrenes thus allowing for an assignment of the oxygenation pattern.9  
After extensive studies with regards to the mysterious ethylamine bridge, Sir 
Robert Robinson proposed the correct structure of morphine (Figure 1.02) in 1925.10 It 
was a remarkable achievement and accounted for every prior and subsequent chemical 
study of the molecule.11 In 1955, Hodgkin published the crystal structure of morphine 
hydroiodide dihydrate thus offering insight into the conformational structure.12 The 































Figure 1.02 Morphine ring system and numbering. 
 
 
1.1.4 Structure Activity Relationship 
Three distinct classes of mammalian opioid receptors µ , δ and κ have been 
identified as being responsible for the CNS activity of opiates. When coupled with G-
proteins they trigger the inhibition of adenylyl cyclase, the enzyme responsible for the 
production of cyclic adenosylmonophoshate (cAMP) production. The lowering of the 
cAMP levels affects the potassium (δ and µ receptor agonism) and calcium (κ receptor 
agonism) ion channels of the cell and, if the opiate use is ceased, leads to a huge surge in 
the cAMP levels thereby triggering a withdrawal. 
Hughes verified the long held belief that morphine mimicked some endogenous 
analgesics (collectively called endorphins- endogenous morphinoids), compounds which 
are produced by the body in response to stress or pain.14 The two enkephalins, met-
enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), were 
characterized by their ability to inhibit the electrically stimulated contraction of guinea 
pig ileum and mouse vas deferens. The structural similarity to morphine, in that the first 
residue of each is a tyrosine, is noteworthy. 
 6 
The structure-activity relationship of the opiates has been well documented.15 
Morphine is selective to the µ-type receptor and thus the analgesia it elicits is 
accompanied by euphoria, physical dependence and respiratory depression; hence, 
overdose can be fatal. On the contrary, agonism of the κ-type is analgesic and does not 
exhibit the side-effects observed in morphine, but instead, is accompanied by strong 
sedative and dysphoric effects. Most of the morphine produced from opium is converted 
into codeine by methylation. It is also a precursor for many drugs like hydromorphone 
(5), and oxycodone (6), Figure 1.03. Replacement of the N-methyl group of morphine 
with an N-phenylethyl group results in a product that is 18 times more powerful than 
morphine in its opiate agonist potency. Combining this modification with the replacement 
of the 6-hydroxyl with a 6-methylene produces a compound some 1,443 times more 
potent than morphine, stronger than the Bentley compounds such as etorphine 7 and as 
such, is only administered to large animals. The quest for finding analogues that are as 
potent as the natural opiates, but, which show less of the negative side-effects, continues 





























A detailed understanding of the biosynthesis of morphine is now complete.16 It 
has been established that the origin of the benzylisoquinoline alkaloid skeleton begins 




































Scheme 1.01 Biosynthesis of (R)-reticuline, the phenolic oxidation precursor. 
 
Two equivalents of L-tyrosine are the source of all non-methyl carbon atoms 
incorporated into morphine, Scheme 1.01. One of the tyrosine molecules is converted 
into dopamine and the other to p-hydroxyphenylacetaldehyde. These are connected by a 
stereospecific Pictet-Spengler type reaction mediated by (S)-norcocalurine synthase to 
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give (S)-norcoclaurine which upon subsequent oxidation and methylation gives (S)-
reticuline. An inversion of configuration occurs by an NADPH-mediated oxidation-
reduction via an iminium species to form (R)-reticuline. This inversion forms the basis 
for the exclusive occurrence of (-)-morphine in nature. 
The most important step in the biosynthesis of morphine is undoubtedly the 
diphenolic oxidation using NADPH-dependent cytochrome P450, salutaridine synthase, 
which forges the link between the two aromatic rings of (R)-reticuline and leads to 
salutaridine, Scheme 1.02. Barton and Cohen originated the idea that this prototypic 
phenolic coupling forms the basis for many C-C and C-O bonds in a variety of alkaloids, 
including morphine.17 Barton demonstrated the conversion of isotopically labeled 
reticuline to salutaridine by treating it with K3Fe(CN)6, albeit in a mere 0.02% yield.
18  
Finally, salutaridine is converted to salutaridinol via an enzymatic NADPH 
reduction. Salutaridinol contains the configuration needed for an allylic syn displacement, 
to undergo ring closure and form thebaine. Thebaine is subsequently transformed to 
neopinone which is then isomerized to codeinone. NADP oxidoreductase in the presence 
of NADPH reduces codeinone stereospecifically to codeine (3). Finally, demethylation of 


































































1.1.6 Previous syntheses 
The pentacylic ring structure with five contiguous stereocenters, one of which is a 
quaternary carbon, in a rather limited array of functional groups makes the synthesis of 
the opiates a challenging task. Thus, Gates’ synthesis of morphine in 195219 was a 
landmark publication in this area. To date more than 20 formal and total syntheses have 
been published, and these have been extensively reviewed in the literature,20 bearing 
testimony to the undiminished interest of synthetic chemists in this molecule.  
As stated earlier, the bio-mimetic phenolic oxidative coupling of reticuline 
derivatives have proved to be of limited value in the synthesis of morphine and its 
congeners. However, formation of the same C12-C13 bond (morphine numbering, unless 
otherwise stated, Figure 1.02) bond by other methods has led to efficient strategies for 
opiate syntheses. Unfortunately, except for Rice’s synthesis21 in 1980, no route has 
shown promise for large-scale manufacturing.  
A complete account of all the previous syntheses is beyond the purview of this 
document and an attempt to classify only the most important syntheses, based on their 
approach, has been made.  
 
1.1.7 First total synthesis (Gates 1952) 
No treatise on the subject of morphine can be complete without outlining the 
monumental work of Robert Gates who, in 1952, completed the first total synthesis of 
morphine.19 This achievement is particularly significant given that the structure was still 
a subject of debate at the time and the crystallographic evidence came three years after 
the synthesis was published. The degradation chemistry of morphine usually ended in 
phenanthrene derivatives, and a majority of the efforts during the time were focused on 
elaborating the phenanthrene nucleus. Thus, Gates’ approach was both unique and bold. 
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The synthesis commenced with the elaboration of the naphthalene diol 8 to the 
dione 9. A Michael-type addition of ethyl cyanoacetate, followed by oxidation, 
hydrolysis and decarboxylation gave the necessary dienophile for the subsequent Diels-
Alder reaction with butadiene to complete the formation of rings A, B and C. This also 
introduced a two carbon handle at the C13 quaternary center in compound 11. A unique 
copper chromite mediated hydrogenation provided the core compound 13, albeit with the 
wrong stereochemistry at C14. Oxidation of the alkene 13 produced the β-
















































Scheme 1.03. Gates’ synthesis of morphine. 
 The incorrect stereochemistry at C14 required stereochemical correction, Scheme 
1.04. The β-dihydrothebainone was treated with bromine followed 2, 4-
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dinitrophenylhydrazine to give the C14 inversion product 15. This was hydrolyzed to the 
enone, reduced to the saturated ketone and again treated with bromine. This introduced 
two bromines, at the C5 and the C7, i.e. both α-positions of ketone 14. When the ketone 
14 was derivatized with 2,4-DNPH, it formed 1-bromocodeinone 16. Finally, reduction 
of the codeinone 16 with lithium aluminium hydride produced codeine, which was 
subjected to a high-temperature demethylation to produce morphine.22 The overall yield 
for the 29 step sequence was just 0.001%, but the strategy not only produced the first 
synthetic sample of morphine, it also succeeded in creating the groundwork for several 
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1.1.8 Phenolic oxidation routes 
Barton’s previous demonstration of the enzyme mediated phenolic oxidative 
coupling in labeled reticuline,23 led to his attempt at achieving this transformation in 
vitro, Scheme1.05. MnO2 promoted oxidation of reticuline to salutaridine 17 proceeded 
in a dismal 0.012% yield, and could only be proven with radioisotope dilution 
experiments.  Reduction, followed by SN2' displacement by the phenolic hydroxyl (18) 































Scheme 1.05. Barton’s bio-mimetic synthesis of thebaine. 
 
The non-enzymatic phenolic oxidation process is non-selective and hence forms 
several products in the process. It was postulated that instead of one electron phenolic 
oxidations, the use of heterolytic bond formation and scission could potentially alleviate 
this problem. Schwartz (1975) proposed the use of a hypervalent iodine based oxidant 
and phenyliodosobis(trifluoroacetate) was identified as the better reagent for this 
conversion.25 Unfortunately, the yield did not improve too dramatically and, the method 
failed to prevent para-para coupling. White’s synthesis (1983) employed a hypervalent 
iodine reagent on a substrate bearing a C1-bromine as a blocking group intended to 
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prevent para-coupling.26 The blocking group idea had gained considerable success in 
previous strategies directed towards morphine. White’s phenolic oxidation step 
proceeded in a modest 10-21% yield. 
Kametani (1969) employed a Pschorr-type cyclization via the diazo derivative of 
2-aminobenzyltetrahydroisoquinoline 19, Scheme 1.06, to achieve a more ortho-selective 
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Scheme 1.06. Kametani’s Pschorr-type cyclization method to form salutaridine (17). 
 
Schäfer (1986) employed a non aromatic A-ring moiety (20) to achieve the 
oxidative coupling using SnCl4, followed by aromatization to salutaridine (17), Scheme 
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Scheme 1.07 Schäfer’s oxidative aryl-alkenyl coupling. 
1.1.9 Cationic cyclization 
A bioanalogous synthesis was achieved by the combined contributions of several 
groups (Morrison, Waite and Shavel 1967)30 and finally adapted to the morphine skeleton 
by Grewe (1967), using phosphoric acid to effect the key cyclization, Scheme 1.08.31 The 
method still suffered from low-regioselectivity and the desired ortho coupling proceeded 
in a poor 3% yield compared to the undesired para-coupled product in 37% yield. The 
acid causes enol ether hydrolysis and trapping of the intermediate cation by the aromatic 


























Scheme 1.08. Grewe cationic cyclization. 
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The Grew strategy was improved upon by Beyerman (1979)32 who introduced a 
benzyl ether C1-blocking group (to prevent para-coupling) to achieve a near-quantitative 
yield of the coupling product (compound 23 in Scheme 1. 08) and a late-stage 
hydrogenolysis effected the removal of the blocking group.  
This idea was improved upon by Rice (1980),21 by employing a C1-bromine as 
the blocking group, Scheme 1.09. The key Grewe-type cyclization on the un-conjugated 
ketone 25, with the C1-bromine, proceeded in 60% yield. This method offered a quick 
assembly of the morphine skeleton in just 8 steps and a remarkable 29% overall yield of 
compound 27. This was transformed in 8 additional steps to morphine in an overall yield 



































1.1.10 Other C13-C15-bond formations. 
As previously stated, a number of early attempts at the assembly of the morphine 
skeleton were focused on the idea of the elaboration of a phenanthrene core. The crucial 
step in such strategies is the formation of the C13-C15 bond to generate the quaternary 
center. Just two years after the first synthesis of morphine was published by Gates, 
Ginsburg (1954)33 published the first phenanthrene-based approach. Condensation of 
ortho-lithiated veratrole with cyclohexanone produced the alkene 29 which was 
transformed to the enone 30, Scheme 1.10. A Michael addition-decarboxylation-Friedel-
Crafts acylation sequence produced the substituted phenanthrene nucleus 31. Introduction 
of the acetoxyamide side chain, followed by cleavage of the C4 methyl ether, resulted in 
a spontaneous formation of the ethylamine bridge. Further elaboration provided the 
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Scheme 1.10 Ginsberg’s approach to the morphine skeleton. 
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Forty years after publication of the first phenanthrene-based route, which by now 
had fallen out of popularity, Mulzer (1996)34 published a synthesis employing a cuprate 
conjugate addition on the C6 isomer of the enone 30. Fuchs (1987)35 employed a tandem 
conjugate addition-alkylation strategy to combine the two halves of the morphine 
skeleton and used the previously established stereochemistry at C5 to direct the 




















Scheme 1.11 Fuchs’ conjugate addition-alkylation approach 
 
Subsequently, White (1997)36 revisited the phenanthrene based approach, in his 
second synthesis, in which the crucial C13-C15 bond was formed via a Rh-catalyzed 
carbenoid C-H insertion reaction using the enantiomerically enriched precursor 33 to 
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Scheme 1.12 C-H activation approach to the construction of (+)-morphine by White. 
 
Evans’ approach (1982) employed an enamine alkylation to synthesize the 
isoquinoline 38, Scheme 1.13.37 Aziridination of the iminium to compound 39 followed 
by oxidation with DMSO, provided the aldehyde 40, which upon Lewis acid treatment 
produced the morphinan 41. Rapoport’s approach (1983) is similar to that of Evans’ in 


























Scheme 1.13 Evans’ aziridination approach. 
 
Taber’s route (2002) used an intramolecular alkylation-Robinson annulation 
cascade as the key disconnection in his approach, Scheme 1.14.39 When the 
enantiomerically enriched keto-aldehyde 42 was heated under basic conditions, alkylation 
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(C13-C15 bond formation) produced the bridged compound 43, which underwent 





















Scheme 1.14 Taber’s enolate alkylation approach to form the quaternary center. 
 
The use of palladium mediated cross coupling in the formation of the morphine 
skeleton was first reported by Overman (1993), Scheme 1.15.40 Beginning with a 
stereocontrolled synthesis of allylsilane 45 and subsequent condensation with the 
aldehyde 46 to produce an intermediate iminium ion, which underwent allylsilane 
cyclization to afford the isoquinoline 47. Palladium-mediated coupling resulted in the 
formation of the C12-C13 bond and produce the morphinan 48, which was subsequently 























Scheme 1.15 Overman’s enantioselective synthesis of morphine. 
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Trost (2002) utilized two successive palladium catalyzed reactions to form the 
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1.2  STUDIES DIRECTED TOWARDS THE SYNTHESIS OF (±)-MORPHINE 
 
1.2.1 Synthetic strategy 
The product of the oxidative coupling of para-cresol, known as the Pummerer’s 
ketone, had been postulated as being the core structure for a variety of natural products.42 
Barton argued that the initially proposed structure of the Pummerer’s ketone was in fact 
the product of a dienone-phenol rearrangement, and therefore incorrect. In the course of 
his studies directed at the synthesis of usnic acid,43 he demonstrated that the correct 
structure was in fact compound 52, Scheme 1.17. A mechanistic rationale for the 














Pummerer's ketone, 52 
 
Scheme 1.17 Oxidative coupling of p-cresol to produce the Pummerer’s ketone (52). 
 
Using this concept, Barton and Cohen demonstrated the in vitro oxidation of 
reticuline to salutaridine by K3Fe(CN)6 and proposed that this prototypic phenolic 
oxidative coupling is responsible for the formation of a variety of natural products, 





























Scheme 1.18 Biomimetic synthesis of (-)-morphine (1). 
 
Barton and Kirby (1960) extended this idea to the biomimetic synthesis of (±)-
galanthamine (57) via a phenolic oxidative coupling in 4'-O-N-dimethylnorbelladine, 
Scheme 1.19.45 They proposed the symmetrical cross conjugated dienone 55 as the 
precursor to narwedine (56), which in turn was known to be the bio-genetic precursor of 




















4'-O-methylnorbelladine, 54 R = H ; N-demethylnarwedine, 55













Interestingly, in the subsequent full paper (1962) detailing the work, (±)-
narwedine 56 was converted to (+)-narwedine with a trace amount of (-)-galanthamine, 
(57). Conversely, (+)-galanthamine was shown to produce (-)-narwedine.45b This method 
was modified and later improved upon by the scientists at Ciba-Geigy, utilizing a 
catalytic amount of (+)-galanthamine in the dynamic resolution of (±)-narwedine to (-)-
narwedine, in very high optical purity and yield, and demonstrated the feasibility on a 
pilot-scale (kilograms).46  
The uncanny resemblance of the skeletal arrangement of morphine and 
galanthamine is quite evident, in that, both resemble the core structure of the Pummerer’s 
ketone. Consequently the strategies used to synthesize these molecules are similar. Most 
syntheses of galanthamine have attempted to forge the C8a-C14 (galanthamine 
numbering, Scheme 1.19) bond via phenolic oxidations45a-b,47 or Heck coupling (Fels, 
Parsons, Guillou/Thal, Trost).48 The idea that the two natural products can be arrived at 
using a common intermediate has been utilized by Trost in his divergent synthesis of 
optically pure morphine and galanthamine, via a common intermediate derived from an 
asymmetric allylic alkylation of phenol derivative.49 
Based on the biosynthesis of galanthamine, we envisioned that if a cross-
conjugated dienone like compound 60 could be synthesized, it could offer the possibility 
of using the same chemical handles via two different transformations to arrive at the two 
structurally similar natural products, (-)-galanthamine and (-)-morphine, Scheme 1.20. 
Such a dienone could be doubly reductively aminated (with the free aldehyde and the 
latent aldehyde in the acetal) to produce racemic narwedine, or be subjected to Henry 
conditions to form the compound 59 which upon reduction and subsequent reductive 
amination could provide us with the morphinan skeleton. More importantly, we were 
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interested in exploring the para-alkylation of an appropriately substituted phenol of the 

















































Scheme 1.20 Common dienone intermediate 60, leading to the two natural products 







The anionic cyclization of phenols is a well established strategy for the synthesis 
of cross-conjugated dienones and, a wide variety of tethers can be used to create the 
quaternary centers.50 Work on utilizing such an approach to the synthesis of galanthamine 
was initiated in the Magnus group by Dr. Benjamin Fauber, a former graduate student.51 
A summary of his work is represented in Scheme 1.21.  
Initial attempts at the arriving at a galanthamine via an intramolecular phenolate 
alkylation of the 1,2-haloethylamine 63 to form the benzoazapine 64, resulted in only the 
dimerization product 65 being observed. The dimerization could not be averted, by 
changing either the solvent concentration or the temperature, and it was reasoned that the 
necessary orbital overlap could not be achieved in the sp3 hybridized substitution pattern.  
In order to rectify the deficiencies of the previous system, the nature of the 
electrophile was altered from a sp3 to sp2 and in the process also render the carbon more 
electrophilic. The sulfoxide solvent was expected to induce a Pummerer rearrangement 
on the halide and render the product 66 more susceptible to attack. However, this 
approach too was unsuccessful and, the only product observed was the product of 
electrophilic aromatic substitution-aromatization, compound 68. 
It was then decided that the tether should be placed on the oxygen instead of the 
benzylic position. This would prevent cyclization onto the aromatic ring, and would force 
para-alkylation. However, the chloroacetate 69 produced only the desilylated phenol 71 













































































Scheme 1.21. Strategies employed in the synthesis of the cross conjugated dienone. 
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1.2.2 Synthesis of the dienone intermediate 
Although the early strategies employed by Dr. Fauber failed to produce a cross-
conjugated dienone, the idea of placing the tether on the phenolic oxygen, was later met 
with success. A brief discussion of the successful strategy towards the synthesis of a 
cross-conjugated dienone is now presented.  
The first step was the synthesis of the biaryl compound 77 using a Suzuki 
coupling reaction. The nucleophile in the Suzuki coupling, the bromoaldehyde 73, can be 
commerically sourced from Aldrich. However, bearing in mind the multi-gram scale on 
which this compound would be required to proceed with the investigation, it was found 
practical to synthesize it by the Friedel-Crafts bromination of isovanillin 72, 
commercially available and inexpensive. The boronic acid trimer 76 was prepared in two 
steps, starting with the protection of the hydroxyl group of commercially available p-
bromophenol 30 as its TBS-ether and subsequent boronylation with triisopropyl boronate. 
It was found that the same methodology could also be employed in the synthesis of the 
TIPS-ether analogue of 76. However, the TBS-ether trimer 76 could be produced in 
consistently high yields, in batches of up to 100g, and the resulting product could be 
conveniently recrystallized from hexanes.  
The two fragments 73 and 76 were coupled under Suzuki coupling conditions to 
form the biaryl compound 77. It was observed that enhanced yields of the biaryl 
compound 77 could be obtained when the solvent system was changed from aqueous 
ethanol (1:3) and aqueous dimethoxyethane (1:3) to aqueous dioxane (1:3). The solvent 
was degassed, using argon, to remove any dissolved oxygen. BHT was added to the 
reaction, as an oxygen scavenger, to inhibit oxidative debromination. The biaryl 
compound 77 was alkylated with 1,2 dibromodiethylether 78 (generated in situ by 



























































Scheme 1.22 Synthesis of the dienone precursor 79. 
 
The key intramolecular phenolate alkylation was performed using CsF to 
desilylate the TBS-protected phenol and generate the phenolate. When the mixture was 
heated to reflux and maintained at 140 °C, intramolecular phenolate alkylation ensued 
and complete conversion to the product 60 was obtained, Scheme 1.23. It was important 
that the reaction be performed under anhydrous conditions; that the CsF and the 
apparatus be flame-dried under high-vacuum and maintained under an argon atmosphere 
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before use. Best results were obtained when the DMF was dried over activated 4 Å 
molecular sieves, for a few days prior to use. When these conditions were strictly adhered 
to, consistently high yields of 90% and above could be obtained on various scales (0.25-
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Scheme 1.23 Intramolecular phenolate alkylation to produce the dienone 60. 
 
 
1.2.3 Henry reaction and selective reduction 
The course of the present study begins with the conversion of the dienone 60 
towards the formation of the morphine skeleton. The first step in this regards required the 
treatment of the dienone 60 under Henry reaction conditions.52 When the dienone 60 was 
treated with nitromethane with a catalytic amount of  ammonium acetate in refluxing 
acetic acid, the nitroalkenes 80a/80b were obtained as a 1:1 mixture of the two 
diastereomers in 65% yield after column chromatography. When the same reaction was 
attempted with a catalytic amount of acetic acid and ammonium acetate in refluxing 
nitromethane, the crude product was obtained in 97% yield, and pure enough to be 
carried forward to the next step without chromatography, Scheme 1.24. 
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It is important to point out here that, only the product of cis ring-fusion was 
obtained. This is presumably due to the fact that the product of trans ring-fusion is highly 
strained in this system. This argument is supported by Spartan energy-minimization 
calculations which show that the trans-isomer is approximately 3 kcal.mol-1 higher in 
























Scheme 1.24 Henry reaction products of the dienone 60. 
 
With this result in hand, we proceeded to reduce the nitroalkenes 80a/80b 
selectively to their corresponding nitroalkanes 81a/81b, Scheme 1.25. The selective 
reduction to the nitroalkanes was necessary as it would provide us the opportunity to 
explore a chiral base catalyzed dynamic resolution to set the absolute stereochemistry at 
the quaternary center similar to the dynamic resolution of narwedine.46  
Although nitroalkenes can be reduced to nitroalkanes using a variety of catalysts 
and reagents,53 there are no reports of the chemoselective reduction of nitroalkenes in the 
presence of an enone moiety. An extensive screening of hydrogenation catalysts to 
selectively reduce nitroalkene 80a to nitroalkane 81a was performed. Pd/C, Pd-BaSO4, 
Pd-CaCO3, Pd-Black,
54 PtO2, Raney Nickel, Zn/AcOH, Al-amalgam and Wilkinson’s 
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catalyst proved ineffective in that, they either returned unreacted starting material or, 



























Scheme 1.25 Products of catalytic reduction. 
 
 
Hydride based reducing agents like NaBH4, Na(OAc)3BH, LiBH4 predominantly 
reduced the enone moiety in a 1,2 manner, accompanied by the desired conjugate 
reduction of the nitroalkane.55 When NaBH4 in 10:1 THF-MeOH was used,
56 an 80% 
yield of the desired nitroalkane (81a) was obtained. In situ formation of sodium 
trimethoxyborohydride from NaBH4 in MeOH has been implicated as the reactive species 
under these reduction conditions.57 The use of commercially available sodium 
trimethoxyborohydride offered improved yields in this chemoselective conversion. When 
sodium cyanoborohydride was employed as the reducing agent only traces of the product 
were seen after 4h. However, with the addition of phosphate buffer (pH = 4.5), complete 
conversion was obtained after 4h. Sodium cyanoborohydride is known to work best at 
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pH~ 3-5 for this reduction.58 Subsequently, it was found to be more practical to replace 


















Scheme 1.26. Selective reduction to the nitroalkane 81a and ORTEP illustration of 81a. 
 
X-ray crystal structure of nitroalkane 81a revealed that the nitro group was 
equatorial, and hence, on the same face as the tethered acetal. This was of critical 
importance, given that the impending reductive amination in the synthetic strategy 
between the tethered acetal and the amine (which would come from the reduction of the 
nitro group) could only be possible if the two groups were on the same face, Scheme 
1.20.  
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This seemingly fortuitous result can be easily explained if one considers that the 
initial product of conjugate reduction is a nitronate anion, which is preferentially 
protonated from the axial face. Alternatively if one were to invoke a thermodynamic 
argument, the acetic acid which can engage in reversible protonation-deprotonation, will 
eventually equilibrate the large nitro group to the less sterically encumbered equatorial 
position. 
Interestingly, the nitroalkanes 81a/81b can also be synthesized by an alternative 
methodology from the biaryl compound 77, Scheme 1.27. The biaryl compound can be 
treated under Henry reaction conditions to produce the β-arylnitroalkene 84 which upon 
reduction with sodium borohydride, gave the β-arylnitroalkane 85. This upon alkylation 
with 1,2-dibromoethylether 78, produced the compound 87. Compound 87 can also be 
obtained by changing the sequence of the two preceding reactions via compound 86. 
When compound 86 was treated under the phenolate alkylation conditions previously 
used in the synthesis of the dienone 60, the reaction failed to produce the expected 
corresponding cross-conjugated dienone with the pendant nitroalkene compound 60a. 
Attempts at performing an intramolecular phenolate alkylation on compound 87 to give 
the nitroalkanes 81a/81b were successful, but, gave us poor yields of the desired 
compound. The reaction predominantly produced the protodesilylation product 88. 
Attempts at converting compound 88 to compound 81/81b by treatment with KOtBu 
failed to achieve the transformation in a variety of solvents even at elevated temperatures 
under sealed tube conditions. Despite its advantages of high yields and ease of 
purification by crystallization of all the intermediates, this strategy had to be abandoned 
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Scheme 1.27 Alternative synthesis of the nitroalkanes 81a/81b. 
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1.2.4 Construction of pentacyclic core and completion of formal synthesis 
The next step in the synthesis required the selective reduction of the nitro group of 
81a/81b to the primary amine 82, Scheme 1.28. Catalytic hydrogenation over Pd/C 
returned starting material. Hydrogenation with Raney Nickel as catalyst produced the 
amine 82 in about 45% yield. Thus, similar to the selectivity problem encountered in the 
conjugate reduction of the nitroalkenes 80a/80b, the reduction of the nitro group to the 
amine, while still keeping the enone intact, was unsuccessful. The key idea in the strategy 
to morphine envisioned the formation of the ethylamine bridge (D-ring) via a sequential 
hydrolysis of the acetal in compound 82 followed by reductive amination with the 
primary amine. Subsequent conjugate addition of the free phenol would then effect the E-
ring closure to form the morphinan 89. Hence, the reduction of the nitro group to the 



































Scheme 1.28. Proposed hydrolysis-reductive amination strategy. 
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When nitroalkane 81b was treated with freshly prepared aluminum amalgam in 
methanolic THF,59 the hydroxylamine 90b was obtained in 75% yield, Scheme 1.29. 
Hydroxylamines are known to undergo condensations with aldehydes to produce 
nitrones. When the hydroxylamine 90b was subjected to acid hydrolysis, nitrone 91 was 
obtained as the sole product of the reaction. This fortuitous result implied that not only 
was the hydrolysis-amination strategy feasible, but an SN2' attack of the free phenol on 
the allylic alcohol moiety could also lead to the intended furan ring closure and thus 


























Scheme 1.29. Cyclization of hydroxylamines 90a/90b under hydrolysis conditions. 
 
The above result obviated the need to retain the enone functionality which had so 
far been crucial for the E-ring formation. We proceeded to reduce the nitroalkanes 
81a/81b to the primary amine using lithium aluminum hydride, which would also reduce 
the enone to an allylic alcohol. On treating the primary amines 92a/92b to aqueous acid 
in the presence of sodium cyanoborohydride,60 complete conversion to the pentacylic 
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Scheme 1.30. Hydrolysis-reductive amination of the amines 92a/92b and completion of a 
formal synthesis. 
 
Upon treatment of the secondary amine 93 with ethylchloroformate, the 
ethylcarbamate 94 was obtained in 90% yield. The ethylcarbamate 94 had previously 
been synthesized in Taber’s (2002) synthesis of morphine.39 Compound 94 was identical 
in all respects to the data published in the manuscript. This completed a formal synthesis 
of morphine employing the idea of intramolecular phenolate alkylation to generate the 




1.2.5 C-ring oxidation  
In Taber’s synthesis of morphine, the ethylcarbamate 94 had been subjected to 
epoxidation followed by ring-opening with sodium phenylselenide, Scheme 1.31 and, 
rearrangement of the selenoxide 96 to the allylic alcohol 97. The overall yield for the 
transformation was low and since most traditional epoxidation conditions had failed to 
epoxidize the molecule, the epoxidation had only been possible with the use of a special 
tungsten catalyst. Moreover, the β-epoxide 95 eventually required stereochemical 
inversion at C5 via oxidation of the incorrect allylic alcohol 97 to codeinone 98 before a 
final LiAlH4 reduction to produce codeine 3. This correction protocol is ubiquitous in the 
morphine area due to lack of methods that can functionalize the C ring from the sterically 
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Scheme 1.31. Taber’s strategy for the C-ring oxidative transposition. 
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Since the rationale for not attempting a classical oxidative transposition of the 
∆6,7-alkene had not been provided in Taber’s report, it was decided that in the course of 
this study an independent exploration of other alternatives for the oxidative transposition 
of the ∆6,7-alkene to the ∆7,8-double bond should be explored. 
The molecular model of the ethylcarbamate reveals certain unique features 
regarding the sterics of the system, represented in Scheme 1.32. As is evident, the α-face 
of the molecule is sterically encumbered while the β-face is relatively unhindered. Any 
conformational change in this pentacyclic ring system is expected to be significantly 
cumbersome, and arguably, the molecule is locked in this form. Most large electrophiles 
would thus be expected to approach the alkene from the β-face.  
Conversely, an ene reaction of small dipolar molecules would require an axial 
proton during the rearrangement, and hence, they would have to approach the alkene 
from the bottom face. Thus the loss of the H8 axial proton would not only rearrange the 
∆6,7-double bond to the ∆7,8-double bond, but would introduce the electrophile at the C6-

































Scheme 1.32. Predicted approach of electrophiles onto the alkene of ethylcarbamate 94. 
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Singlet oxygen is well known to engage in ene-reactions with alkenes.61 The ene-
reaction was expected to proceed with axial approach on the α-face of the alkene and 
produce the hydroperoxide 98a, Scheme 1.33. Singlet oxygen for these reactions was 
generated using a mercury lamp and sensitizers such as tetraphenylporphyrin and Rose 
Bengal. However, the reaction only returned an intractable mixture of products. When 
palladium and ruthenium catalyzed Wacker-type oxidations were attempted, starting 
material was fully recovered.62 
The ethyl carbamate 94 was treated with CrO3-3,5 dimethylpyrazole, a reagent 
combination well known to oxidize alkenes to enones (with alkene transposition).63 The 
reaction resulted in severe decomposition of the material. Similarly when selenium 
dioxide was used, extensive decomposition occurred.64  
Since, ene-reaction type oxidation conditions had failed to induce the predicted 
rearrangement, other methods to functionalize the alkene were explored. Epoxidation of 
the ethylcarbamate 94 using mCPBA and trifluroperaceticacid led to extensive 
degradation of the starting material.65 Epoxidations with hydrogen peroxide and t-
butylhydroperoxide using oxo-Vanadium complexes and iron (VI) complexes as catalysts 
failed as well.  
All of the hyper-reactivity of this substrate to these oxidations can be attributed to 
the presence of the highly electron-rich aromatic ring, which is expected to be quite 














































Scheme 1.33. Attempted oxidative transformations of the alkene.  
 
A well established protocol in steroidal chemistry for the functionalization of the 
sterically hindered β-face, is to employ bromohydrin formations.66 The large bromonium 
ion approaches the alkenes in such molecules from the less sterically encumbered (α-face 
in case of steroids) and opens the epi-bromonium ion to a bromohydrin. Subsequent 
treatment with base forms an epoxide on the β-face of the molecule.  
When the ethylcarbamate 94 was treated with dibromohydantoin in aqueous THF, 
the bromohydrin 99 was obtained in 97% yield, Scheme 1.34. As speculated earlier, the 
first product of the reaction was indeed the bromination of the electron-rich aromatic ring 
and complete conversion to the bromohydrin was only seen after 12h. The bromohydrin 
was treated with solid KOH in toluene and heated at reflux for 2 h, after which complete 
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conversion to the epoxide 100 was seen. Thus, the initially formed β-epi-bromonium ion 
is first opened by axial attack of water at C6, to produce the bromohydrin 99 with the 
stereochemistry depicted. This is subsequently closed to an α-epoxide. The two steps can 
be combined into a one-pot procedure when aqueous dioxane is used for the first step. 
After complete conversion to bromohydrin 99 has occurred, KOH is added to the flask 
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Scheme 1.34. Epoxidation via bromohydrin formation. 
 
In Taber’s synthesis of morphine, the α-epoxide had been treated to sodium 
phenylselenide and subsequently oxidized to the selenoxide and eliminated to the allylic 
alcohol, Scheme 1.31. However the report did not mention if traditional epoxide-allylic 
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alcohol rearrangement conditions had been attempted. With this idea in mind, the epoxide 
100 was treated with Al(iPrO)3 in refluxing toluene, a well known method to induce this 
rearrangement, Scheme 1.35.67 However, no allylic alcohol was seen even after several 
days at reflux, (Table 1.01). Similarly, when Ti(iPrO)4 was used, no rearrangement 
product was observed. Use of Lewis acid activators like TMSOTf and TIPSOTf and 
BF3.OEt in the presence of a base (DBU) did not induce the rearrangement.
68 Harsher 
conditions like DBN in refluxing xylenes and increasing the temperature to over 200 °C 
in sealed tube led to degradation of the compound to a complex mixture. This could be 
due to the fact that severe steric congestion on α-face of the molecule prevents the 





















Scheme 1.35. Rearrangement of the epoxide 100 to the allylic alcohol 101. 
 
The use of lithium dialkylamides and harpoon bases such as metal-
tetramethylpiperidides did not yield any allylic alcohol 101.69,70 When the epoxide 
opening was attempted using LDA and other lithium dialkylamides, no evidence of 
epoxide opening was seen by 1H-NMR and a complex mixture was produced in the 
reaction. This could be due to degradation of the molecule caused by dehydrobromination 
of the bromoarene by LDA.71  
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Condition Result Condition Result 
Al(OiPr)3/toluene/reflux Recovered s. m. 
LDA/THF/-78 °C Complex 
mixture 
Ti(OiPr)4/toluene/reflux Recovered s. m. 
LiNEt2/THF/-78 °C Complex 
mixture 
DBU/ benzene/reflux Recovered s. m. 















 /THF/0 °C 
Complex 
mixture 
KH/ THF/sealed tube 
140 °C 
Recovered s. m. 
NLi)2 / THF/ -78 °C Complex 
mixture 
Table 1.01 Conditions attempted to convert the epoxide 100 to the allylic alcohol 101.   
 
The expected base-mediated epoxide opening had failed to achieve the desired 
rearrangement to the allylic alcohol 101. As stated earlier, this was believed to be due to 
the steric hindrance on the α-face which prevented the syn-geometry required for such an 
elimination from being attained. An anti-elimination pathway could potentially be more 
favored.  
With this idea in mind, we explored other alternatives to the functionalization of 
the alkene using the bromohydrin formation concept. When the ethylcarbamate 94 was 
treated with 1,3-dibromo-5,5dimethylhydantoin in acetic acid, the product of the reaction 
the acetoxy-bromide 106, was obtained in 89% yield, Scheme 1.36. This compound was 
crystalline and, the X-ray structure (Figure 1.04) revealed that the acetate group was at 
the C7α position and the bromide was in the C6β position. At first, it would seem like the 
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observed product is contrary to what is expected from an axial opening of the epi-
bromonium ion (Scheme 1.34). However, it is reasonable to assume that the initial 
product could indeed be the expected axial opening product 102a, and this subsequently 







































































Figure 1.04 ORTEP representation of acetoxybromide 102. 
 
That the observed regiochemistry of the acetoxybromide 102 is contrary to the 
predicted regiochemistry (102a), should have no bearing on the dehydrobromination 
reaction. Both would form the same acetoxonium intermediate via assistance from the α-
acetoxy group. Treatment of compound 102 with silver acetate in benzene was expected 
to form the allylic acetate 103 via anti-elimination. The soft Ag+ counterion would assist 
the departure of the bromide. Neighboring group participation from the C7-acetate 
moiety, would then form the stable acetoxonium intermediate which could collapse to the 
allylic acetate. However, only a trace of the allylic acetate 103 was obtained from this 
reaction. When the acetoxy-bromide 102 was heated with excess DBU in refluxing 
xylenes, only a trace of the allylic acetate 103 was observed, accompanied by extensive 
decomposition of the substrate. When compound 102 was heated in quinoline at 210 °C, 
the allylic acetate was obtained in about 15% yield. The high temperature required for the 
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reaction and low yield obtained from it made it impractical to pursue this reaction any 
further. 
Owing to the failures of various methods to effect rearrangement of the epoxide 
100, it was decided that the previously demonstrated protocol established by Taber would 
be applied to the molecule.39 On treating the epoxide 100 to sodium phenyl selenide 
(freshly prepared by the reduction of diphenyl diselenide with sodium borohydride) 93% 
yield of the selenide 104 was obtained, Scheme 1.37. Subsequent oxidation using NaIO4 
and elimination of the isolated selenoxide 105 under basic conditions in refluxing 
benzene, produced complete conversion to the allylic alcohol 101. 
The use of selenide on larger scales did not portend well for scale up, particularly 
with regards to the toxicity associated with such compounds and it was thought best to 
explore a less toxic sulfur analogue. The epoxide opening was performed using freshly 
prepared sodium phenylsulfide. However, the subsequent oxidation with NaIO4 did not 
produce any sulfoxide. The use of hydrogen peroxide in hexafluroisopropanol, a method 
which reputedly prevents over-oxidation of the initially formed sulfoxide to the sulfone,72 
was attempted. Isolation of the sulfoxide 107 and elimination produced the allylic alcohol 
in 76% yield. It is worth mentioning here, that no the sulfoxide elimination did not occur 
in refluxing benzene and the elimination required a higher temperature. Hence, the 




















































































Scheme 1.37. Epoxide opening and oxidation-elimination to allylic alcohol 101. 
 
The 1H-NMR spectrum of the crude product obtained in the sulfoxide elimination 
showed two signals in the aromatic region in the ratio 1:4. This was surprising, because 
no change in the aromatic region would be expected under these reaction conditions. On 
close examination it was found that a few other signals in the aliphatic region of the 
spectrum, showed unexpected peaks in the same molar ratio. It was concluded that the 
product must therefore be a mixture of two compounds. Mass spectroscopy data revealed 
that the product had the same elemental composition as the allylic alcohol. Further 
evidence was obtained from the 13C-NMR spectrum, which showed a peak at δ = 200, 
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indicating the presence of a saturated carbonyl group in one of the compounds in the 













































Scheme 1.38. Elimination pathways for the diastereomeric sulfoxides 107a/107b. 
 
Collating all of the aforementioned spectral evidence, it was established that the 
by-product was in fact the saturated ketone 108 formed during the oxidation-elimination 
sequence performed on the phenylsulfide 104, Scheme 1.38. The two products can be 
explained from the fact that during the oxidation of the sulfide 106 to the sulfoxide two 
diastereomeric forms of the sulfoxide 107a/107b are produced. In sterically unhindered 
systems, the elimination always proceeds away from the carbon bearing the hydroxyl 
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group by rotation about the C-S bond. The energy barrier for such rotation is usually 
significantly lower than the energy required for rehybridization at the hydroxyl bearing 
carbon. 
 However, in this molecule, such a rotation would require the phenyl group to 
pass over the β-face of the C-ring. This in all probability is much more energetically 
demanding than the energy required for rehybridization. The diastereomeric ratio of the 
two sulfoxides formed during oxidation would hence determine the ratio of the two 
products formed in the [2,3]-sigmatropic rearrangement. The selectivity in case of the 
selenoxide can be explained by the fact that the length of the C-Se bond is higher by 
approximately 20 pm. than the C-S bond and hence rotation about this bond is expected 
to be less sterically demanding, which is probably the reason why both the selenoxides 
105a/105b produce the allylic alcohol product 101, exclusively. 
In an effort to alter this ratio in favor of the desired sulfoxide, the oxidation was 
performed at 50 °C. This increased the ratio of the ketone to allylic alcohol from the 
previous 1:4 (23 °C) to 1:5. When the oxidation was carried out at 0 °C, the ratio was 1.9: 
1. Thus, it was clear that appropriate conditions could alter this ratio significantly, and it 
might even be possible to achieve the elimination without formation of the side-product 
by changing the alkyl group on the sulfur to a group smaller than a phenyl.73 
All that remained to complete the synthesis of codeine, was to remove the 
aromatic bromide and convert the carbamate to the N-CH3 group. Lithium aluminum 
hydride is known to effect the substitution of the aromatic bromide with a hydride in the 
morphine system as far back as Gates’ first total synthesis of the molecule.19 Similarly, 
the conversion of the carbamate to the N-Me has also been performed on this molecule 
by using LiAlH4. Treatment of the allylic alcohol 101 with lithium aluminum hydride at 0 






























Scheme 1.39. Reduction and completion of total synthesis.  
 
 
Finally, treatment of the racemic codeine 3 with BBr3 in chloroform,
74 effected 
the demethylation of the aromatic methoxy group to produce morphine in 85% yield. 
This completed the total synthesis of (±)-morphine employing for the first time an 
intramolecular phenolate alkylation strategy to generate the quaternary center of the 
molecule. The overall yield is 17% for the 14 step reaction sequence and this represents 
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Pharmacological activity of the opiates is significantly dependent on the absolute 
configuration.1 It was found that there are two classes of receptors that mediate the 
effects of morphine; the ones that are highly stereospecific and the ones that are less 
discriminatory. The ones that are stereospecific are receptors for the endogenous ligands, 
the endorphins, which mitigate pain, while the receptors of the second kind, which are 
less selective, are responsible for the hyper-reactive motor behavior induced by the 
opiates. For instance, (-)-morphine and naloxone (an opiate drug widely used to counter 
the effects of opiate overdose) block the receptors of the first kind, while they fail to bind 
to the receptors of the second kind.  In contrast, (+)-morphine and dextromorphan, which 
do not bind to the receptors of the first kind, impart no analgesia. Instead (+)-morphine 
shows only the hyperexcitability that follows (-)-morphine administration, indicating that 
it binds to the second receptor. Dextromorphan in fact is not an analgesic and is used as a 
cough suppressant. It has been an ongoing quest of the pain-management industry to find 
analogues that are less addictive but equally analgesic and thus mitigate the negative 






2.0.1 Previous strategies for the enantioselective synthesis of (-)-morphine. 
Due to a lack of syntheses of morphine which are truly practical on large scales, a 
classical resolution is not a viable alternative to produce the unnatural (+)-isomer. The 
(+)-isomer, required for the previously mentioned biological studies, was synthesized 
from (-)-sinomenine (123). Sinomenine is a naturally occurring substance, structurally 
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Scheme 2.01 Conversion of (-)-sinomenine to (+)-morphine 
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The enantioselective synthesis of morphine, without the use of resolution, was 
first reported by Overman (1993)3 and subsequently by White (1997)4 and Trost (2002)5. 
These syntheses have been previously discussed in Chapter 1. The syntheses reported by 
Mulzer (1996),6 Ogasawara (2001),7 Taber (2002)8 and Parker (2006)9 require chiral 
resolution of an early intermediate and the diastereocontrol for all the other stereocenters 




































Scheme 2.02. Formation of the quaternary center in previous enantioselective syntheses. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Strategy to achieve enantioselectivity in the system under study 
Before outlining the synthetic strategy envisioned for achieving enantioselectivity 
in the system under study, it is important to note some key features of the dienone 
molecule, compound 60 (Scheme 2.03). 
1) The dienone 60 is axially symmetric.   
2) The stereochemistry at the quaternary center will depend upon which of the two 
enones is favored by the chiral catalyst towards conjugate addition. 
3) The product of the nitroaldol reaction between the aromatic aldehyde and 
nitromethane results in only the desired cis ring-fusion product. 
4) The product of the above reaction would result in a mixture of four isomers, two of 
which have the same stereochemistry about the chiral center, and the other two the 
opposite. 
5) In the subsequent reactions, since the acetal stereocenter is destroyed by hydrolysis, 
the four isomers formed initially will now only be two, each with opposite 
stereochemistry at the quaternary center, i.e. enantiomers. 
6) If the chiral catalyst system was indeed successful in biasing one enone over the other 
(i.e. one of the two colored pathways depicted in Scheme 2.03), the final outcome 
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Scheme 2.03. Influence of the stereochemistry of conjugate addition on the final 
stereochemical outcome of the reaction sequence.  
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2.2.2 Dynamic resolution 
Our first idea to achieve enantioselectivity was loosely based on the dynamic 
resolution-type process, similar to the one used in the Ciba-Geigy method10 for the 
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Scheme 2.04 Ciba-Geigy dynamic resolution of (±)-narwedine. 
We had envisioned a similar set-up for the racemic nitroalkane 81a, that, in the 
presence of a chiral base a retro-Michael reaction could generate the free nitronate which 


























Scheme 2.05. Proposed dynamic resolution of nitroalkane 81a. 
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In order to test if this hypothetical process is feasible, we carried out deuterium 
labeling studies. When the nitroalkane 81a was heated with triethylamine in deuterated 
methanol and deuterium oxide for 12h, the trideuterated product 112 was observed by 1H-
NMR, Scheme 2.06. If the retro-Michael reaction had indeed taken place, the axially 
symmetric dienone would have resulted in deuterium incorporation at both the enone 
positions to give the tetradeuterated compound 113. The presence of just the trideuterated 


























































Figure 2.01. 1H-NMR of the deuterated compound indicating the absence of deuterium 





The addition of L-proline, which we had expected could form an enamine with 
the ketone in 81a and facilitate the retro-Michael process (Scheme 2.07), showed no 
deuterium incorporation either. When this reaction was attempted using a mixture of 
pyrrolidine and acetic acid (catalytic) and heated in refluxing toluene, again no deuterium 
incorporation was observed.  With this, the idea of attempting a dynamic resolution using 
a chiral base was abandoned. It was concluded that the retro-Michael reaction was 































2.2.4 Enantioselective nitroaldol-conjugate addition reaction 
There are several methods available for the enantioselective nitroaldol reactions 
reported in literature and numerous reviews have been published on this topic.11 
Similarly, the enantioselective conjugate addition of nitroalkanes onto activated alkenes 
is also well precedented.12 Although the substrate scope for these two classes of reactions 
is fairly wide, there are no definitive parameters established for making an educated 
choice of the catalyst. Our strategy required the conjugate addition step to be 
enantioselective, but we reasoned that since the nitroaldol reaction preceded the 
conjugate addition step, an enantioselective nitroaldol catalyst could provide an optically 
enriched nitroalcohol which in turn could be more selective to one of the two enones. 
Some catalysts are known to catalyze both, the enantioselective nitroaldol as well as the 
enantioselective conjugate additions of nitronates, and as a starting point we chose to 
explore such catalyst systems.13  
Our first choice was the use of the Shibasaki heterobimetallic catalyst14 (115, 
Scheme 2.08) which was prepared using the reported literature procedure.15 Treatment of 
the dienone with the catalyst and nitromethane at -40 °C resulted in complete 
consumption of the dienone and the formation of several compounds (TLC). Two of the 
major products were found to be the desired nitroalcohols 114a/114b and the other the 
nitroether 116.  Attempts at controlling the reaction to produce just the two desired 









































Scheme 2.08. Nitroaldol reaction with Shibasaki’s (R)-LaLB catalyst. 
 
 
Copper-sparteine complexes are also known to impart high enantiomeric excesses 
to nitroaldol reactions as well as conjugate additions of nitronates to enones.16 The 
copper-sparteine complex was prepared under the reported conditions and subjected to 
the nitroaldol reaction. The predominant product under various reaction conditions was 



































Scheme 2.09 Cu-sparteine catalyst in the nitroaldol reaction. 
 
 
Zinc triflate in the presence of chiral 1, 2-aminoalcohols has been known to 
catalyze and exhibit a high degree of enantioselectivity in nitroaldol reactions.17 
Consequently, treatment of the dienone under the conditions depicted in scheme 2.10 
gave 60% yield of the two nitroalcohols 114a/114b. However, the two nitroalcohols 
showed no optical rotation; clearly there was no enantiomeric excess imparted to the 
molecule by the catalyst. When the solvent was changed to toluene instead of 
dichloromethane, less than 10% conversion occurred at 23 °C even after 4 days of 
stirring. When the same reaction was carried out at higher temperatures, complete 
conversion occurred, but several products corresponding to the various nitroalcohol 
isomers and the cyclized form were observed (TLC), rendering the catalyst system 




































Scheme 2.10. Zn-NME catalyst system for the nitroaldol. 
 
 
2.2.3 Isolation of uncyclized nitroalcohol  
Before proceeding any further with the screening of other catalyst systems to 
achieve the intended enantioselective conjugate addition, we were interested in 
disengaging the two sequential steps that provide us with the desired nitroalcohol; i.e. 
isolation of the intermediate uncyclized nitroalcohol, before the conjugate addition could 
occur, Scheme 2.11. The uncyclized nitroalcohol 117 could then be dehydrated to the 
nitroalkene 118, which would allow us to explore Baylis-Hillman type conditions using 
chiral tertiary amine /chiral phosphine to dictate the stereochemistry of the conjugate 




































Scheme 2.11. Chiral Baylis-Hillman-type intramolecular coupling of the nitroalkene to 
the enone to set the stereochemistry at the quaternary center. 
 
When a solution of the dienone 60 in THF was added to a suspension of n-
butyllithium in nitromethane at -78 °C, initially, no conversion was observed. However, 
when the cooling bath was allowed to warm to -30 °C, two spots were observed by TLC 
analysis. The reaction mixture was quenched at this stage and the products were isolated 
using preparative TLC. 1H-NMR of the two compounds isolated indicated that the 
aldehyde signal was no longer present, but the dienone signals were still seen, making it 
safe to assume that these were indeed the product of the first addition, the uncyclized 
nitroalcohols 119a/119b, Scheme 2.12. However, 13C-NMR of the products could not be 
obtained since under the mildly acidic conditions of the NMR solvent, CDCl3, the two 
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compounds had cyclized to the corresponding cyclic nitroalcohols 114a/114b. The 







































Scheme 2.12. Isolation of uncyclized nitroalcohols.  
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This was an important result, since it demonstrated that the initial products, the 
uncyclized nitroalcohols 119a/119b, were susceptible to ring closure under both acidic 
and basic conditions and hence the idea of a dehydration without ring-closure was not 
viable. Secondly, since each of the products had given rise to a 1:1 mixture of the two 
cyclic nitroalcohols 114a/114b, it implied that the stereochemistry at the benzylic 
position had no bearing on the selectivity of the enone face. Thus, it was critical that the 
focus be diverted from the enantioselective nitroaldol step to the enantioselective 
conjugate addition step in order to achieve any enrichment at the quaternary center. 
 
2.2.4 Chiral phase-transfer catalysis 
Chiral phase transfer catalysis has been a front runner in enantioselective 
organocatalysis and takes advantage of the fact that most phase transfer catalysts are 
water soluble, and the products can be easily separated due the biphasic nature of these 
systems. The first truly practical use of this methodology came from the Merck process 
group in 1984, in the alkylation of phenylindanone derivatives using N-alkylated 
cinchonine.19 Since then, the idea has been extended to various transformations and the 
pool of available chiral phase transfer catalysts has increased manifold.   
When the dienone 60 was treated with nitromethane and potassium carbonate 
using the catalyst N-benzylcinchonidinium chloride, complete conversion to the two 
nitroalcohols 114a/114b was observed. The nitroalcohols individually showed a strong 
optical rotation indicating that the catalyst system had succeeded in inducing 





































Scheme 2.13 Chiral phase-transfer catalyzed nitroaldol reaction 
For the purposes of determining the enantiomeric excess (ee), it was thought 
prudent to convert the two isolated nitroalcohols 114a/114b to a previously synthesized 
intermediate en route to the synthesis of morphine. First, the selective reduction of the 
nitroalcohol 114a to the nitroalkane 81b was attempted. However, various reductive 
conditions failed to effect the benzylic alcohol cleavage, Scheme 2.14.  
Treatment of the nitroalcohol to methanesulfonylchloride and triethylamine 
converted the nitroalcohol 114a to the corresponding nitroalkene 80a. Thus the product 
of the enantioselective step could be introduced into the previously completed synthesis 
without having to make making any major changes to the overall synthetic design. The ee 
of the nitroalkene 80a thus formed was found to be 27% by chiral HPLC using an ODH 




























Scheme 2.14 Conversion of the enantioenriched nitroalcohol 114a to the previously 
synthesized nitroalkene 80a. 
 
With the success of the method in achieving a slight enantiomeric excess, 
optimization of the reaction conditions was initiated. First, a variety of carbonates were 
screened to effect the conversion. The bases Li2CO3, MgCO3, BaCO3 were found to be 
too unreactive towards the reaction, even at room temperature. Na2CO3, K2CO3, Cs2CO3 
were found to be increasingly reactive (in that order) at room temperature. Since, it had 
been previously observed that the conjugate addition step was fast at higher temperatures 
(Scheme 2.12), the reaction would need to be conducted at a low temperature in order to 
facilitate higher selectivity during the conjugate addition. When the temperature of the 
reaction was lowered to 0 °C, Na2CO3 was unreactive and at -20 °C K2CO3 was found to 
be unreactive, even over long reaction times. Although Cs2CO3 was unreactive at -78 °C, 
it was reactive above -20 °C. Thus, the ideal bases for this reaction were found to be 






Entry Base Solvent Temperature Time 
Enantiomeric 
excess (ee) 
1 Cs2CO3 MeNO2 0 °C 8h 27% 
2 Na2CO3 MeNO2 23 °C 48h 20% 
















-20 °C 72h 50% 
 
 
Table 2.01 Optimization of the reaction conditions for the N-benzylcinchonidinium 
chloride catalyzed enantioselective nitroaldol reaction. The ee’s reported are 





In neat nitromethane and using K2CO3 as the base, the ee observed for the 
nitroaldol product was 20%. Under identical conditions Cs2CO3 imparted an ee of 27%. 
When the reaction was carried out in a 1: 1 mixture of nitromethane to toluene using 
K2CO3 as the base, the ee improved to 50%. Clearly, lower temperatures and increase in 
toluene concentration were inducing greater selectivity in the reaction. When the solvent 
system was changed to 1: 10 nitromethane to toluene using Cs2CO3, the ee improved to 
80%.  
The dramatic improvement in ee with the lowering of the polarity of the solvent 
system (increase in toluene concentration) can be attributed to two factors. 
1) The non-polar interactions between the positively charged catalyst and toluene would 
enhance the binding of the catalyst to the nitronate anion, during catalysis. 
2) Reduction in the equivalents of nitromethane would reduce the possibility of a 
background reaction, one in which the nitronate is disengaged from the chiral 
catalyst. 
 
It was found that the highest enantiomeric excess was obtained when the 
nitroaldol reaction was performed using cesium carbonate as the base in a solvent 
mixture of nitromethane and toluene in the ratio 1:10, at -20 °C. The reaction took 24h 
for complete conversion of the dienone to the two nitroalcohols 114a/114b, and the 







Further optimization was beyond the purview of the present study. The isolation 
of the two nitroalkenes 80a/80b each with an ee of 80%, was deemed satisfactory for the 
purpose of a “proof-of-concept” investigation.  However, it remains to be seen if the 
stereochemistry at the quaternary center, imparted by the phase-transfer catalyst N-
benzylcinchonidinium chloride, is identical to that of natural morphine. If otherwise, N-
benzylcinchoninium chloride, the commercially available antipode of this catalyst, should 
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The Amaryllidaceae are a family of herbaceous, perennial and bulbous flowering 
plants included in the monocotyledonous order Asparagales and take their name from the 
genus Amaryllis. The roughly 1100 species of plants in this family are mostly deciduous, 
rarely shrubby or treelike plants, often with bulbs, and rarely, with rhizomes.  
Around the world, the Amaryllidaceae family has found its place in the garden as 
ornamentals.1 However, a huge number of plants are traded for traditional medicines as 
well. Use of the bulbs and leaves as poultices and decoctions for treating sores and 
digestive disorders is widespread among Africans. However, in large dosages these can 
prove to be extremely poisonous. The Zulu people of South Africa also use rhizomes of 
clivias as protective charms. In Peru, the Inca people frequently depicted flowers of the 
Amaryllidaceae (Ismene, Pyolirion and Stenomesson) on ceremonial drinking vessels. In 
cool temperate climates, Narcissus (daffodils), Leucojum (snowflakes) and Galanthus 
(snowdrops) are among the most important spring-flowering bulbs in commerce. 
Elsewhere, in warm temperate and subtropical climates, species of Amaryllis, Clivia, 
Hippeastrum, Nerine, and Zephyranthes are the most popular choices for gardens and 
containers.  
The plants of the Amaryllidaceae family have attracted considerable attention due 
to their content of alkaloids with interesting pharmacological activities.2 Until recently, 
the Amaryllidaceae alkaloids have been classified structurally mainly into seven 
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subgroups, namely lycorine (1H-pyrrolo[3,2,1-d,e] phenanthridine type), crinine (5,10b-
ethanophenanthridine type), narciclasine (isocarbostyril type), galanthamine (6H-
benzofuro[3a,3,2-e,f]-2- benzazepine type), tazettine (2-benzopyrano[3,4-c] indole type), 
lycorenine (2-benzopyrano[3,4-g]indole type) and montanine (5,11-
methanomorphanthridine type).3a-b As a result of extensive phytochemical studies more 














Figure 3.01. Core structures of the alkaloids of the Amaryllidaceae family. 
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3.1.1 Isolation and Structure 
Galanthamine, the most sought after among the Amaryllidaceae alkaloids, was 
first reported as a constituent of the Caucasian snowdrop (Galanthus woronowii) in 
1952.5 Its structure was confirmed by Uyeo and Kobayashi through degradation studies 
in 19576a-b and, the absolute configuration was established as (-)-galanthamine by Barton 
and Kirby.7  The extraction process provides about 10-100mg of galanthamine per 
kilogram of the raw plant material and the cost results in a price tag of $50,000 per 





































3.1.2 Pharmacology  
 
Alzheimer ’s disease (AD) is an incurable, degenerative, terminal disease which is 
one of the most common forms of dementia. Of the three hypotheses for the cause of the 
disease, the oldest, the cholinergic hypothesis states that the primary cause of AD is the 
reduction in the neurotransmitter acetylcholine (Ach). Acetylcholinesterase inhibitors are 
used to reduce the rate at which acetylcholine is broken down, and thus combat the loss 
of Ach. Galanthamine, is one such long acting, selective, reversible and competitive 
acetylcholinesterase inhibitor.9a-c The atomic resolution 3D structure of the complex of 
galanthamine and its target, acetylcholinesterase, was determined by X-ray 
crystallography in 1999.10 However, there is no evidence that galanthamine alters the 
course of the underlying ‘dementing’ process. It is also used in the treatment of 
myasthenia gravis, an autoimmune disease which causes muscle weakness and fatigue.11 
For a long time, galanthamine has been used in Eastern Europe in the symptomatic 
treatment of poliomyelitis.12 It is also used as an anti-curare agent,13 and as a 
parasympathomimetic drug.14 It is the most recently approved AchE inhibitor in Europe 
and US for the treatment of mild-to-moderate Alzheimer’s disease.15 Presently, it is 






3.1.3 Previous syntheses 
The first total synthesis of galanthamine was reported by Barton and Kirby in 
1960 by the oxidative coupling in 4'-O-N-dimethylnorbelladine 120, thus validating their 











































Subsequently, the synthesis of galanthamine has been improved upon by various 
research groups. The primary disconnections are similar to the strategies employed for 
the synthesis of morphine (discussed in Chapter 1), namely, the phenolic oxidative 
coupling18a-m and metal-catalyzed oxidative coupling19a-c of the A and C rings. There are 
also some other unique methods exclusively aimed at the synthesis of galanthamine.20a-j 
Currently, commercial supplies of the molecule are available from Sanochemia 
AG using the Fröhlich-Jordis route, Scheme 3.02.21 The key phenolic oxidative coupling 
step using K3Fe(CN)6 proceeds in a modest 40-54% yield. This process route utilizes the 
Carlson-Shieh dynamic resolution procedure to convert (±)-narwedine using (+)-
galanthamine to (-)-narwedine in the penultimate step.22 The final step involves the 
reduction of (-)-narwedine using L-selectride to provide (-)-galanthamine in 99% yield. 
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Scheme 3.02. Sanochemia AG process route to (-)-galanthamine. 
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3.1.4 Previous work in the Magnus group  
 
Previous studies in the Magnus group on the synthesis of (-)-galanthamine had 
envisioned the synthesis and double reductive amination of the dienone 60 with 
methylamine to provide (±)-narwedine, the precursor to (-)-galanthamine. This idea was 
initially pursued by Dr. Benjamin Fauber, then a graduate student in the lab and 
subsequently by a post-doctoral researcher Dr. Kimberley Seibert. However, various 
conditions and strategies at utilizing the dienone had not provided a scalable and 






























































































Scheme 3.03. Previous work in the Magnus group towards the synthesis of narwedine. 
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3.3 RESULTS AND DISCUSSION 
In all of the previous attempts at the double reductive amination, the hydrolysis of 
the acetal, followed by the reductive amination was always attempted as a two step 
process. Having established in the morphine work (Chapter 1) that the hydrolysis-
reductive amination could be performed sequentially in one step and, that the isolation of 
the imine was unnecessary, we envisioned using a similar approach in the construction of 
the seven-membered ring of narwedine from the dienone 60. 
Our prior experience in these reductive aminations had shown us that the use of 
methylamine as a solution in THF and other organic solvents for reductive aminations 
suffered from inconsistent results. Moreover, a bottle of methylamine (in solution) once 
opened, did not have a good shelf-life and could not be stored for more than 2-3 days. 
Older bottles would not only fail to aminate, but in fact, lead to complete decomposition 
of the reaction mixture. Owing to this, we decided to explore conditions in which the 
methyl amine could be liberated in situ within the reaction medium.  
When a solution of the dienone 60 in dioxane was treated with methylamine 
hydrochloride and diisopropylethylamine followed by NaCNBH3, complete conversion to 





















Scheme 3.04. Synthesis of the tricyclic amine 129a/129b. 
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When the amine 129a/129b was subjected to hydrolysis under acidic conditions 
(1N HCl), followed by addition of NaCNBH3, the major product of the reaction was the 
hydrolyzed acetal product 130, Scheme 3.05. This product failed to reductively aminate 






















Scheme 3.05. Hydrolysis of the tricyclic amine under reductive conditions 
 
In order to avoid the hydrolysis product 130, the acetal cleavage was performed in 
the presence of in 10% HCl in ethanol. However, the reductive amination to narwedine 
did not occur and the 1H-NMR of the product showed the presence of several signals 
corresponding to the ethoxy group indicating that the saturated ketone may have formed 
the diethylketal under these conditions.  
The failure of the one-step hydrolysis reductive amination protocol in this system 
can be attributed to the large energy barrier required to form the seven-membered D-ring 
from an existing six-membered tertiary amine. When the reductive amination fails, the 
competing 1,4 addition of the intermediate hemi-acetal results in the closure to the 
























































It was clear that the competing conjugate addition pathway was to be avoided. 
One possible method was prior formation of the furan ring. This was achieved by the 
hydrolysis of the dienone 60 to the lactol 131 using aqueous hydrochloric acid in 
refluxing dioxane, in 93% yield, Scheme 3.07. The molecule has no available enone for 





















Scheme 3.07. Hydrolysis of the dienone  
 
Treatment of the lactol with methylamine hydrochloride and N,N-
diisopropylethylamine followed by treatment with NaCNBH3 in acetic acid resulted in 
complete conversion to what was initially speculated to be the β-hydroxy ketone 132, 
Scheme 3.08. The 1H-NMR of the product showed the AB doublet of the benzylic 
protons and the proton at C4a (furan) that is a characteristic feature in the spectrum of 
narwedine. However, the enone signals were absent. We reasoned that that product was 
most likely the result of a stepwise amination, first with the benzaldehyde and 
subsequently with the oxonium ion generated from the lactol. Prominent signals in the IR 
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spectrum included the 1718 cm-1 of the saturated ketone and an unexpected doublet at 
2200 cm-1 and singlet at 2414 cm-1. X-ray analysis of the compound explained this 
unusual pattern by indicating the presence of a BH2CN moiety on the tertiary nitrogen via 
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When the borane adduct 132a was heated with mesyl chloride and pyridine, 
complete conversion to a less polar compound (TLC) occurred.  This was speculated as 
being the mesylate of the β-hydroxyketone and was expected to readily eliminate to 
narwedine. When the resulting solution was heated with additional triethylamine, two 
products were observed by TLC; one having a similar Rf to narwedine and the other, 
more polar. Isolation of the individual products by preparative TLC and characterization 
by 1H-NMR revealed that the N-methyl signal was conspicuously absent in the product.  
When a TLC analysis of the two separated compounds was performed, it was 
observed that each of the compounds was again a mixture of the two separated ones. 
Based on the spectral evidence, the compounds can be assigned the structures 135 and 
135a. The two products are believed to be an equilibrating mixture of the free secondary 
amine and the free phenol.  
This equilibrating mixture has been previously observed by Jordis et. al. in their 
work related to the demethylation of narwedine.23 Compound 135a is in fact                  
N-demethylated narwedine. Based on the mechanistic evidence presented in the citation, 







































Scheme 3.09. Demethylation product. 
 
In order to prevent chloride assisted demethylation, observed during the mesylate 
elimination, the conversion of the β-hydroxy ketone to the enone was carried out via 
acetylation-elimination, Scheme 3.10. When the borane adduct 132a was treated with a 
mixture of acetic anhydride and sodium acetate and heated at reflux in dioxane, complete 
conversion to narwedine (56) was observed. It is reasonable to assume that in the absence 
of a decomplexing agent such as pyridine, the nitrogen is still bound to the boron and 
hence unable to engage in the intramolecular SN2 reaction observed in the intermediate 































Scheme 3.10. Elimination via acetylation. 
 
A convenient method to disable neighboring group participation by the tertiary 
nitrogen, would be to perform the reaction under strongly acidic conditions which would 
lead to protonation of the nitrogen and render it non-nucleophilic. However, treatment of 
the hydroxy compound 132a under various acidic conditions (aq. H2SO4, acetic acid, etc.) 
did not produce narwedine. Treatment of the compound 132a under basic conditions (aq. 
sodium hydroxide) resulted in complete decomposition of the material.  
When a solution of the compound 132a in dioxane was treated with an aqueous 
solution of methanesulfonic acid (1M) and heated for several hours, complete conversion 
to a product identical in Rf to an authentic sample of narwedine was observed by TLC. 























Scheme 3.11. Acid catalyzed elimination to (±)-narwedine. 
 
Subsequent optimizations established that recrystallized methylamine 
hydrochloride provided the best yields of the β-hydroxy ketone 132a. The crude product 
can be subjected to the dehydration conditions without purification. The dehydration was 
performed under refluxing dioxane with 20% methanesulfonic acid (aq.), Scheme 3.11. 
Complete conversion to narwedine was obtained and the overall yield for the three steps 
from the dienone 60 to narwedine is 67%.  
The dynamic resolution of racemic narwedine to (-)-narwedine and the 
subsequent reduction to (-)-galanthamine has been well established and proceeds in 97% 
yield. Thus, the aforementioned synthesis of racemic narwedine constitutes a formal 
synthesis of (-)-galanthamine. The overall yield of the six step procedure, beginning with 
2-bromoisovanillin, is 63% which is five times the yield of Sanochemia AG’s 
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CHAPTER 4: EXPERIMENTAL SECTION 
 
4.0 GENERAL INFORMATION 
 
Melting points were taken on a Thomas-Hoover capillary tube apparatus, and are 
uncorrected. Infrared spectra were recorded on a Thermo-Nicolet Avatar 360 FT-IR 
spectrophotometer, with the sample neat on KBr plates, unless otherwise indicated. 1H 
and 13C NMR spectra were recorded on Varian 400 MHz DirectDrive NMR at 400 MHz 
and General Electric QE-300 spectrometer at 300 MHz, in the indicated solvent, and are 
reported in ppm relative to tetramethylsilane, or referenced internally to the residually 
protonated solvent.  Mass spectra were obtained on a VG ZAB2E, or a Finnigan TSQ70 
mass spectrometer.  
Routine monitoring of reactions was performed using Merck 60 F254 glass-
backed silica gel TLC plates.  Flash column chromatography was performed using EMD 
silica gel (particle size 0.040-0.063 µm).  Solvents and commercial reagents were 
purified in accordance with Perrin and Armarego1 or used without further purification. 
All reactions were conducted under an argon atmosphere, and solvents were degassed 
only when specified.  
The determination of enantiomeric excess was performed using High performance 
liquid chromatography (HPLC) on a Waters 515 Binary HPLC pump fitted with a PDA 
detector (model # 2996) using a Chiralcel® OD-H column (4.6mm x 250mm) 
manufactured by Daicel Chemical Industries, LTD. The concentration of the analyte was 
approximately 1.0 mg mL-1 and the injection volume was 25 µL. The eluant used was a 
3: 7 mixture of isopropyl alcohol and hexanes with a flow rate of 0.8 mL min-1. Optical 
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rotations were performed using an Atago POLAX-2L optical resolution polarimeter with 
a 1.0 mL x 100 mm Atago glass observation tube at the specified temperature (°C), 



































To a stirred suspension of isovanillin 72 (10 g, 66 mmol), powdered anhydrous 
sodium acetate (10.82 g, 0.132 mol) and iron powder (0.3 g, 5.4 mmol) in glacial acetic 
acid (60 mL) under argon, was added drop-wise over 15 min a solution of Br2 (3.7 mL, 
0.0726 mol) in acetic acid (12.5 mL). The reaction temperature rose during the course of 
addition, and the mixture became viscous. After all the starting material was consumed, 
as judged by TLC, the mixture was poured onto ice cold water, and the resulting 
precipitate filtered under vacuum. The precipitate was washed several times with cold 
water and air dried. Crystallization from boiling ethanol gave 73 (11.93 g, 79 % yield) as 
a grey powder.  
Rf = 0.10 (1:5 EtOAc/hexanes). M.p. 196-200 °C. IR (thin film) 3215, 1662, 
1588, 1561, 1491, 1273 cm-1. 1H NMR (300 MHz, CDCl3) δ 10.27 (1H, s), 7.59 (1H, d, J 
= 9 Hz), 6.96 (1H, d, J = 9 Hz), 6.02 (1H, bs), 4.00 (3H, s). 13C NMR (75MHz, CDCl3) δ 
56.58, 109.24, 112.84, 113.84, 122.74, 143.25, 151.65, 190.87. HRMS calcd. for 
C8H8O3Br (MH












 To a stirred solution of p-bromophenol (30 g, 0.1734 mol) in 1, 2-
dichloroethane (300 mL) at 23 °C was added imidazole (29.45 g, 0.433 mol). After 15 
min, tert-butyldimethylsilylchloride (28.75 g, 0.190 mol) was added, and the resulting 
solution heated at reflux for 3 h. The mixture was cooled to room temperature and poured 
onto saturated aqueous NH4Cl and extracted with CH2Cl2 (3 x 200 mL). The combined 
extracts were washed with brine (200mL), dried (NaSO4), filtered and evaporated in 
vacuo. The crude product was distilled via short-path distillation (0.5 mm Hg, 130 °C) to 
give (4-bromo-phenoxy)-tert-butyl-dimethylsilane (49.6 g, 99.5% yield) as a colorless 
oil.  
Rf = 0.80 (1:3 EtOAc/hexanes). IR (thin film) 3390, 2951, 2928, 1584, 1479, 
1250 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.34 (1H, d, J = 9 Hz), 6.74 (1H, d, J = 9 Hz), 
1.00 (12H, s), 0.21 (6H, s). 13C NMR (75 MHz, CDCl3) δ 154.76, 132.22, 121.83, 
113.55, 25.58, 18.12, -4.54. HRMS calcd. for C12H20BrOSi (MH


























To a solution of (4-bromo-phenoxy)-tert-butyl-dimethylsilane 75 (10 g, 35 mmol) 
in THF (25 mL) at -78 °C was added drop-wise n-butyllithium (2.4 M in hexanes, 17.5 
mL, 42 mmol) resulting in a yellow colored solution. After stirring the mixture for 30 
min, freshly distilled triisopropoxyborate (24.2 mL, 105 mmol) was added drop-wise to 
the above solution, and the mixture was stirred overnight and allowed to warm to room 
temperature. The mixture was poured onto 10% aqueous KHSO4 (50 mL) and extracted 
with EtOAc (3 x 150 mL). The combined extracts were washed with brine (200 mL), 
dried (Na2SO4), filtered and evaporated in vacuo. The crude white solid was dried by 
azeotroping in toluene (3 x 20 mL), and recrystallized from hexanes/EtOAc to give 
needle shaped crystals of 76 (6.9 g, 84.5 % yield).  
Rf = 0.12 (1:5 EtOAc/hexanes). M.p.118-120 °C. IR (thin film) 2955, 2928, 2854, 
1592 cm-1. 1H NMR (300 MHz, CDCl3) δ 8.13 (2H, d, J = 8 Hz), 6.97 (2H, d, J = 8 Hz), 
1.03 (9H, s), 0.27 (2H, s). 13C NMR (75 MHz, CDCl3) δ 159.7, 137.4, 119.8, 25.7, 18.3, -
4.3. HRMS calcd. for C36H58B3O6Si3 (MH















To a degassed (30 min) mixture of 1,4-dioxane (22.5 mL) and water (7.5 mL) was 
added powdered K2CO3 (2.48 g, 18 mmol), 72 (1.53 g, 6.6 mmol), 76 (1.5 g, 6 mmol), 
2,6-di-tert-butyl-4 methylphenol (BHT) (spatula), and tricyclohexylphosphine (67 mg, 
0.24 mmol). The mixture stirred for 15 min at 23 °C and [Pd2(dba)3] (0.114 g, 0.12 
mmol) was added, and then heated at reflux for 1 h until all starting material was 
consumed, as judged by TLC. The resulting dark colored solution was poured onto 
saturated aqueous NH4Cl (200 mL) and extracted with EtOAc (3 x 150 mL). The 
combined extracts were washed with brine (200 mL), dried (Na2SO4) and concentrated in 
vacuo to yield a yellow solid. Purification by flash column chromatography (SiO2, 15% 
EtOAc/hexanes) gave 77 (2.1 g, 87.9% yield) as a pale yellow solid.  
Rf = 0.20 (1:5 EtOAc/hexanes). M.p. 103-106 °C. IR (thin film) 3401, 2930, 
2857, 1684 cm-1. 1H NMR (300 MHz, CDCl3) δ 9.69 (1H, s), 7.65 (1H, d, J = 9 Hz), 7.24 
(1H, d, J = 9 Hz), 6.98 (1H, d, J = 9 Hz), 6.95 (1H, d, J = 9 Hz), 5.67 (1H , bs), 4.02 (3H, 
s), 1.02 (9H, s), 0.26 (6H, s). 13C NMR (75MHz, CDCl3) δ 191.6, 155.7, 150.8, 142.7, 
132.0, 131.5, 128.4, 120.5, 119.8, 109.6, 56.2, 25.6, 18.2, -4.4. HRMS calcd. for 
C20H27O4Si (MH















To a solution of Br2 (0.397 mL, 7.74 mmol) in CH2Cl2 (30 mL) at 0 °C was added 
drop-wise ethyl vinyl ether (0.92 mL, 9.68 mmol) until the solution turned colorless. The 
mixture was stirred for 15 min and diisopropylethylamine (2.71 mL, 15.48 mmol) was 
added followed by a drop-wise addition of a solution of 77 (1.5 g, 3.87 mmol) in CH2Cl2 
(15 mL). The mixture was stirred for 12 h under argon to give an orange-red solution. 
After complete consumption of staring material, as judged by TLC, the mixture was 
poured onto saturated aqueous NaHCO3 and extracted with CH2Cl2 (3 x 50 mL). The 
combined extracts were washed with brine (100 mL), dried (Na2SO4), filtered and 
evaporated in vacuo to give an orange-red oil. Purification by flash column 
chromatography (SiO2, 10% EtOAc/Hexanes) gave 79 (1.92 g, 92 % yield) as a colorless 
syrupy liquid. (1.92 g, 92% yield).  
Rf = 0.42 (1:5 EtOAc/hexanes). IR (thin film) 2956, 2930, 2857, 1684 cm
-1. 1H 
NMR (300 MHz, CDCl3) δ 9.64 (1H, s), 7.85 (1H, d, J = 9 Hz), 7.25-7.18 (2H, m), 
7.03(1H, d, J = 9 Hz) , 6.93 (2H, d, J = 9 Hz), 5.01(1H, dd, J’s = 7, 4 Hz), 3.98 (3H, s), 
3.56 (1H, m), 3.31 (1H, m), 3.09 (2H,m), 1.05 (2H, t, 7 Hz), 1.01 (9H, s), 0.24 (6H,s). 13C 
NMR (75 MHz, CDCl3) δ 191.5, 157.02, 155.8, 141.7, 140.6, 132.5, 128.5, 125.2, 119.7, 
111.0, 103.7, 64.5, 55.9, 31.8, 25.6, 18.2, 14.9, -4.4. HRMS calcd. for C24H34O5SiBr 
(MH+) 509.1359, found 509.1356.  
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Cross-conjugated cyclohexadienone 60  
                                                                                 







A flame-dried mixture of CsF (0.22 g, 1.44 mol) and Na2SO4 (0.68 g, 4.8 mmol) 
was added to a solution of 79 (0.26 g, 0.48 mmol) in DMF (3.7 mL, stored over 4Å 
molecular sieves) and the reaction mixture was heated at 130 °C for 1.5 h. After 
completion of the reaction, as judged by TLC, the reaction mixture was poured into 
saturated aqueous NaHCO3 (25 mL) and extracted with EtOAc (4 x 20 mL). The 
combined extracts were successively washed with water (3 x 25 mL), brine (50 mL), 
dried (Na2SO4), filtered and concentrated in vacuo to give a brown syrup. Purification by 
flash chromatography (SiO2, 30% EtOAc/hexanes) gave compound 60 (0.137 g, 95.5% 
yield) as thick orange oil which solidified upon standing to an orange solid.  
Rf = 0.23 (1:1 EtOAc/hexanes). M.p. 74-80 °C. IR (thin film) 2983, 2932, 2889, 
1684, 1663, 1586 cm-1. 1H NMR (300 MHz, CDCl3) δ 9.95 (s, 1H), 7.75 (1H, dd, J’s = 
10, 3 Hz), 7.64 (1H, d, J = 9 Hz), 7.04 (1H, J’s = 10, 3 Hz), 6.98 (1H, d, J = 9 Hz), 6.38 
(1H, dd, J’s = 8, 2 Hz), 6.36 (1H, dd, J’s = 8, 2 Hz), 5.15 (1H, t, J = 2 Hz), 4.00 (s, 3H), 
3.96 (1H, m), 3.70 (1H, m), 2.40 (1H, dd, J’s = 14, 2 Hz), 2.01 (1H, dd, J’s = 14, 2 Hz), 
1.22 (3H, t, J = 7 Hz). 13C NMR (75 MHz, CDCl3) δ 189.6, 184.4, 155.8, 155.5, 154.5, 
140.1, 128.7, 126.0, 123.3, 122.8, 110.7, 94.8, 64.7, 56.2, 40.2, 39.8, 15.0. HRMS calcd. 
for C18H19O5 (MH






















A mixture of the dienone 60 (1.0 g, 3.18 mmol), NH4OAc (0.98 g, 12.7 mmol), 
and nitromethane (1.01 mL, 19.08 mmol) in acetic acid (15 mL) was heated at reflux for 
2 h. After completion of the reaction, as judged by TLC, the solvent was evaporated in 
vacuo and the residue was washed with water (40 mL) and extracted with diethylether (3 
x 50 mL). The combined extracts were washed with brine (50 mL), dried (Na2SO4), 
filtered and concentrated in vacuo to give a brown solid. Purification by flash 
chromatography (SiO2, 20% EtOAc/hexanes) gave bright yellow crystals of the two 
diastereomers 80a and 80b (0.72 g, 63% yield) in approximately 1:1 ratio.  
Data for 80a. Rf =  0.45 (1:1 EtOAc/Hexanes). M.p. 161-164 °C. IR (thin film) 
2974, 2926, 2853, 1684, 1570 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.58 (1H, d, J = 2 
Hz), 7.00 (1H, d, J = 9 Hz), 6.90 (1H, d, J = 9 Hz), 6.75 (1H, dd, J’s = 10, 1.5 Hz), 5.92 
(1H, d, J = 10 Hz), 5.59 (1H, d, J = 3 Hz), 3.95 (1H, m), 3.96 (3H, s), 3.70 (1H, m), 3.45 
(1H, dd, J’s = 4, 2 Hz), 3.27 (1H, dd, J = 9, 1.5 Hz), 2.88 (1H, dd, J = 18, 5 Hz), 2.70 
(1H, dd, J’s = 13, 1.5 Hz), 2.33 (1H, dd, J’s = 13, 3 Hz), 1.20 (3H, t, J = 7 Hz). 13C NMR 
(75 MHz, CDCl3) δ 194.9, 152.3, 147.4, 140.4, 132.2, 126.9, 123.9, 121.3, 110.9, 96.2, 
68.1, 64.6, 56.1, 43.1, 37.2, 36.2, 34.4, 29.64, 15.1. Both the structures of 80a and 80b 
were elucidated by X-ray.  
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Data for 80b. Rf =  0.47 (1:1 EtOAc/hexanes). M.p. 165-170 °C. IR (thin film) 
2920, 2842, 1685, 1565 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.56 (1H, d, J = 2 Hz), 6.96 
(1H, d, J = 8 Hz), 6.86 (1H, d, J = 8 Hz), 6.48 (1H, dd, J’s = 10, 2 Hz), 5.98 (1H, d, J = 
10 Hz), 5.38 (1H, dd, J’s = 9, 3 Hz), 4.16 (1H, m), 3.92 (3H, s), 3.74 (1H, m), 3.50 (1H, 
m), 3.28 (1H, dd, J’s = 6, 2 Hz), 2.89 (1H, dd, J’s = 18, 5 Hz), 2.66 (1H, dd, J’s = 13, 3 
Hz), 2.27 (1H, dd, J’s = 13, 9 Hz), 1.29 (3H, t, J = 7 Hz). 13C NMR (75 MHz, CDCl3) δ 
194.6, 150.0, 146.9, 141.4, 132.2, 128.7, 123.9, 121.3, 111.3, 97.7, 65.3, 56.1, 42.1, 39.1, 
38.8, 34.2, 15.1. HRMS calcd. for C19H20NO6 (MH





To the dienone 6 (5.0 g, 15.93 mM) in nitromethane (50 mL), was added 
NH4OAc (0.5 g) and acetic acid (5 mL) and the solution was heated at reflux for 2.5 h. 
When 6 had been consumed, as judged by TLC, the mixture was poured into brine (50 
mL) and the layers separated. The aqueous layer was successively washed with ether (2 x 
40 mL). The combined organics were dried (Na2SO4) and concentrated in vacuo to give 
(5.5 g, 97 % yield) of 80a/80b as a mixture of two diastereomers in a 1:1 ratio. NMR 









Procedure for the synthesis of the nitroalkenes 80a/80b from the chiral nitroalcohols 
114a/114b. 
 
To a solution of the nitroalcohol 114a (20 mg, 0.54 mM), in THF (2mL) was 
added triethylamine (0.3 mL) followed by methanesulfonyl chloride (0.06 mL, 0.80 mM) 
and the solution was heated at reflux until complete conversion to the nitroalkene 80a 
was observed as judged by TLC. The reaction mixture was poured into saturated 
NaHCO3 solution (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organics 
were washed with brine (5 mL), dried (Na2SO4) and concentrated in vacuo to give a 
bright yellow solid (16 mg, 85% yield). For the purpose of HPLC analysis, the compound 
was recrystallized from hot toluene to give the title compound as bright yellow needle 































To a solution of the nitroalkenes 81a/81b (127 mg, 0.36 mmol) in THF (3.5 mL) 
and acetic acid (1.5 mL) was added NaBH3CN (23.5 mg, 0.37 mmol) in small portions, 
and the resulting solution was stirred at for 4 h until all the starting material was 
consumed as judged by TLC. The mixture was poured into aqueous NH4Cl (5 ml) and 
extracted with EtOAc (3 x 5 mL). The combined organic extracts were washed with brine 
(15 mL), dried (Na2SO4), filtered and concentrated in vacuo to give a pale yellow solid. 
Purification by flash column chromatography (SiO2, 30 % EtOAc/hexanes) gave 13 and 
13a as white solids (112 mg, 88% yield)..  
Data for 81a. Rf = 0.55 (1:1 EtOAc/Hexanes). M.p. 201 °C. IR (thin film) 2975, 
2932, 1685, 1551 cm-1. 1H NMR (300 MHz, CDCl3) δ 6.87 (2H, m), 6.06 (1H, d, J = 10 
Hz), 5.50 (1H, dd, J’s = 8, 6 Hz), 4.92 (1H, m), 4.10 (1H, m), 3.88 (3H, s), 3.67 (1H, m), 
3.33 (2H, m), 2.86 (3H, m), 2.46 (1H, d, J = 18 Hz), 2.00 (1H, dd, J’s = 13, 8 Hz), 0.26 
(3H, t, J = 7 Hz). 13C NMR (75 MHz, CDCl3) δ 194.0, 152.0, 148.6, 141.0, 128.5, 125.2, 
122.2, 121.5, 112.5, 98.2, 83.8, 64.4, 56.2, 43.6, 42.4, 38.1, 35.9, 33.2, 29.6, 14.9; HRMS 
calcd. for C19H22NO6 (MH
+) 360.1447, found  360.1443. Structures of 81a and 81b by X-
ray.  
Data for 81b. Rf = 0.57 (1:1 EtOAc/Hexanes). M.p. 168 °C. IR (thin film) 2975, 
2932, 1684, 1551 cm-1. 1H NMR (300 MHz, CDCl3) δ 6.84 (1H, d, J = 9 Hz), 6.82 (1H, 
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dd, J’s = 10, 4 Hz), 6.73 (1H, d, J = 9 Hz), 6.06 (1H, d, J = 10 Hz), 5.50 (1H, dd, J’s = 8, 
6 Hz), 4.92 (1H, m), 4.10 (1H, m), 3.88 (3H, s), 3.67 (1H, m), 3.33 (2H, m), 2.86 (3H, 
m), 2.46 (1H, d, J = 18 Hz), 2.00 (1H, dd, J’s = 13, 8 Hz), 0.26 (3H, t, J = 7 Hz). 13C 
NMR (75 MHz, CDCl3) δ 194.0, 152.0, 148.6, 141.0, 128.5, 125.2, 122.2, 121.5, 112.5, 
98.2, 83.8, 64.4, 56.2, 43.6, 42.4, 38.1, 35.9, 33.2, 14.9. HRMS calcd. for C19H22NO6 
































To a solution of the biaryl compound (0.1g, 0.26 mmol) in nitromethane (2ml) 
was added NH4OAc (0.015g, 0.19 mmol) and the solution was heated at reflux for 12 h. 
The solvent was evaporated under vacuum and the crude mixture was washed with water 
(15 ml) and extracted with EtOAc (3 x 15 ml) washed with washed with brine (20 ml), 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a yellow solid. 
This was subjected to flash column chromatography (SiO2, 20% EtOAc/Hexanes) to 
yield the title compound as a bright yellow solid (0.1g, 97% yield).  
Rf 0.60 (1:1 EtOAc/Hexanes); M.p. 122-124°C IR (thin film) 3526, 2956, 2930, 
2858, 1602, 1514, 1482, 1339, 1271, 1119, 912, 839, 804, 783 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.82 (1H, d, J = 14 Hz), 7.28 (1H, d, J = 14 Hz), 7.25 (1H, d, J = 8 Hz), 7.16 
(2H, d, J = 8 Hz), 6.96 (2H, d, J = 8 Hz), 6.93 (1H, d, J = 8 Hz), 5.66 (1H, s), 4.00 (s, 
3H), 1.02 (9H, s), 0.27 (6H, s); 13C NMR (75 MHz, CDCl3) δ 155.8, 149.3, 143.4, 138.5, 
135.9, 131.6, 130.1, 126.4, 122.7, 120.3, 120.2, 109.2, 56.2, 18.2, -4.3; HRMS calcd. for 
C21H28NO5Si [MH















            NaBH4 (0.2g, 3.44 mmol) was stirred in 10:1 THF/MeOH (15ml) for 30 mins. 
The resulting solution was added drop-wise to a solution of the nitroalkene (1.0g, 1.81 
mmol) in a 10:1 mixture of THF/MeOH (35ml) cooled to -40 °C, until all starting 
material was fully consumed by TLC. The reaction mixture was warmed to -10 °C and 
quenched with a few drops of saturated NH4Cl and 30 ml of water followed by extraction 
with EtOAc (3 x 25 ml). The combined organic layers were washed with brine (30 ml), 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a pale yellow 
liquid. This was subjected to flash column chromatography (SiO2, % EtOAc/Hexanes) to 
yield the title compound as a colorless liquid (0.86g, 86% yield).  
Rf 0.67 (1:1 EtOAc/Hexanes) M.p. 80-82°C; IR (thin film) 3507, 2956, 2930, 
2858, 1553, 1514, 1484, 1263, 1168, 1121, 1030, 1012, 913, 840, 805, 782 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.15 (2H, d, J = 8 Hz), 6.96 (2H, d, J = 8 Hz), 6.81 (1H, d, J 
= 8 Hz), 6.75 (1H, d, J = 8 Hz), 5.54 (1H,s), 4.23 (2H, t, J = 8 Hz), 3.91 (3H, s), 3.12 
(2H, t,  J = 8 Hz), 1.02 (9H, s), 0.26 (6H, s); 13C NMR (75 MHz, CDCl3) δ 155.3, 146.0, 
143.4, 131.0, 130.8, 127.8, 127.0,  120.5, 120.4, 109.8, 75.5, 56.0, 31.0, 31.1, 25.6, 25.6, 
18.2, -4.4; HRMS calcd. for C21H29NO5Si [MH


















A solution of Br2 (0.1ml, 2.0 mmol) in DCM (8ml) under argon, was cooled to 0 
°C. To this, ethyl vinyl ether (0.24ml) was added drop-wise until the solution turned 
colorless. After 15 mins. of stirring, diisopropylethylamine (0.7 ml, 4.0 mmol) was added 
followed by a drop-wise addition of a solution of the biarylnitroalkene compound (0.4g, 
1.0 mmol) in DCM (4ml). The reaction mixture was stirred for 12 h under argon. After 
complete consumption of staring material, checked by TLC, the reaction mixture was 
poured into saturated NaHCO3 (20ml) and extracted with DCM (3 x 20ml). The 
combined organic layers were washed with brine (30 ml), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo to give an orange solid. This was subjected to flash 
column chromatography (SiO2, % EtOAc/Hexanes) to yield the title compound as a 
bright yellow solid (0.44g, 80% yield).  
Rf 0.29 (1:5 EtOAc/Hexanes); M.p. 113-115°C ; IR (thin film) 2930, 1589, 1512, 
1476, 1340, 1263, 1126, 1011, 912, 839, 805 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.76 
(1H, d, J = 14 Hz), 7.46 (1H, d, J = 8 Hz), 7.31 (1H, d, J = 14 Hz), 7.13 (2H, bs), 6.99 
(2H, d, J = 8 Hz), 6.96 (1H, d, J = 8 Hz), 5.00 (1H, dd, J = 7, 4 Hz), 3.97 (3H, s), 3.57 
(1H, m), 3.31(1H, m), 3.08 (2H,m), 1.05 (3H, t, J = 7 Hz), 1.02 (9H, s), 0.26 (6H, s); 13C 
NMR (75 MHz, CDCl3) δ 155.9, 155.3, 142.7, 139.2, 138.1, 136.0, 132.0, 127.0, 124.8, 
122.8, 120.1, 111.5, 103.7, 64.4, 55.9, 31.7, 25.7, 18.2, 14.9, -4.4; HRMS calcd. for 
C25H34NO6SiBr [MH











NaBH4 (0.2g, 3.44 mmol) was stirred in 10:1 THF/MeOH (15ml) for 30 mins. 
The resulting solution was added drop-wise to a solution of the nitroalkene (1.0g, 1.81 
mmol) in a 10:1 mixture of THF/MeOH (35ml) cooled to -40 °C, until all starting 
material was fully consumed by TLC. The reaction mixture was warmed to -10 °C and 
quenched with a few drops of saturated NH4Cl and 30 ml of water followed by extraction 
with EtOAc (3 x 25 ml). The combined organic layers were washed with brine (30 ml), 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a pale yellow 
liquid. This was subjected to flash column chromatography (SiO2, % EtOAc/Hexanes) to 
yield the title compound as a colorless liquid (0.86g, 86% yield).  
Rf 0.40 (1:5 EtOAc/Hexanes); IR (thin film) 2931, 2957, 1607, 1557, 1515,1481, 
1435, 1262, 1169, 1124, 1012, 913, 841, 782, 731 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.15 (1H, dd, J = 8, 2 Hz),  7.10 (1H, dd, J = 8, 2 Hz), 6.98 (1H, d, J = 9 Hz), 6.93 (2H, d, 
J = 8 Hz), 6.85 (1H, d, J = 9 Hz), 4.97 (1H, t, J = 6 Hz), 4.12 (2H, t,  J = 7 Hz), 3.86 (3H, 
s), 3.56 (1H, m), 3.26 (1H, m), 3.24 (2H,m), 1.05 (3H, t, J = 7 Hz), 1.00 (9H, s), 0.24 
(6H, s); 13C NMR (75 MHz, CDCl3) δ 155.3, 151.9, 142.8, 136.8, 131.8, 130.9, 128.6, 
127.0, 125.8, 120.2, 120.1, 111.3, 103.7, 75.3, 64.2, 55.9, 31.9, 31.1, 25.7, 25.6, 18.2, 
14.9, -4.4; HRMS calcd. for C25H34NO6SiBr [MH















The aluminum amalgam required for the reaction was prepared as follows: 100 
mg of aluminum foil was cleaned with hexanes and cut into thin strips. The strips were 
immersed into an aqueous solution (5ml) of HgCl2 (1%) for 30 s, followed by water for 
10 s and finally THF for 10 s.  
To a solution of the nitroalkane 90a 100mg (0.28 mM) in 9:1 THF/MeOH (10ml) 
was added freshly prepared aluminum amalgam (100mg). The suspension tuned gray 
after 20 min and complete consumption of starting material to product was observed, as 
judged by TLC. The slurry was filtered over Celite and washed several times with ether. 
The combined washings were washed with brine (10 ml), dried (Na2SO4) and 
concentrated in vacuo to give a foamy white solid (72 mg, 75% yield) which was used 
without purification for the subsequent step. The compound can be purified via flash 
column chromatography (SiO2, 5% MeOH/CHCl3) to give the title compound 90b as a 
white foam (42 mg, 87%).  
Rf = 0.54 (10% MeOH/CHCl3). IR (thin film) 3355, 3276, 2972, 2931, 1611, 
1580, 1498, 1440, 1276, 1230, 1129, 1044 cm-1. 1H NMR (300 MHz, CDCl3) δ 6.78 (1H, 
d, J = 8.4 Hz), 6.70 (1H, d, J = 8.4 Hz), 5.90 (1H, d, J = 10 Hz), 5.79 (1H, dd, J = 10, 4 
Hz), 5.47 (1H, dd, J = 8, 6 Hz), 4.20 (1H, t, J = 4.3 Hz), 4.11 (1H, m), 3.85 (3H, s), 3.80 
(1H, bs), 3.67 (1H, m), 3.46 (1H, dt, J = 10, 5 Hz), 2.84-3.02 (3H, m), 2.53 (1H, dd, J = 
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13, 4.2 Hz), 2.10-2.30 (3H, m), 1.96 (1H, d, J = 10 Hz), 1.62 (1H, dd, J = 13, 8 Hz), 1.23 
(3H, t, J = 7 Hz). 13C NMR (100 MHz, CDCl3) δ 147.6, 134.0, 128.4, 127.9, 126.6, 
121.5, 111.5, 99.3, 64.0, 61.7, 56.3, 56.2, 56.1, 43.0, 39.0, 38.2, 32.7, 26.8, 15.0. HRMS 
calcd. for C19H26NO5 [MH

































To a solution of the hydroxylamine 90b (100 mg, 0.29 mM) in dioxane (10 mL) 
was added 2.5 N HCl (3 mL) and the solution was heated at reflux for 2.5 h. The reaction 
mixture was poured into cold water (10 mL) and basified to pH~8 with 1N NaOH. The 
resulting solution was extracted with EtOAc (4 x 20 mL). The combined organics were 
washed with brine (20 mL), dried (Na2SO4) and concentrated in vacuo to yield a pale 
yellow solid (56 mg, 65% yield). Spectral data was obtained without purification. 
Rf = 0.62 (10% MeOH/CHCl3). IR (thin film) 3100, 2973, 2930, 1652, 1506, 
1457, 1276, 1044 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.02 (1H, t, J = 3.6 Hz), 6.77 (1H, 
d, J = 8.3 Hz), 6.61 (1H, d, J = 8.3 Hz), 5.87 (1H, m), 5.76 (1H, m), 5.07 (1H, s), 3.85 
(3H, s), 3.02 (1H, d, J = 18.5 Hz), 3.00 (1H, dd, J’s = 18.5, 5.7 Hz),  2.82 (1H, s), 2.68-
2.79 (3H, m), 2.05 (1H, dt, J = 18, 6 Hz), 1.57 (1H, dd, J = 15, 4 Hz). 13C NMR could not 
be obtained due to dimerization of the product at high concentrations in the NMR 
solvent. HRMS calcd. for C17H18NO3 (MH
























To a solution of the nitroalkanes 81a/81b (468 mg, 1.3 mmol) in THF (15 ml) 
cooled to -78 °C under argon, was added LiAlH4 (2M in THF, 3.9 mL) drop-wise over 20 
min. The resulting solution was stirred at -78 °C for 1 h and allowed to warm to R.T over 
8h. The reaction was checked for completion, judged by TLC, and then added to 
saturated aqueous Na2SO4 (5 ml) at 0 °C. The salts were filtered through a Buchner 
funnel and washed with (100 ml) of ether. The organic layer was washed with brine (15 
ml), dried (Na2SO4), and concentrated in vacuo to yield a pale yellow foamy solid. The 
crude product was purified by column chromatography only for the purpose of 
characterization. (SiO2, 1% NEt3, 10% MeOH, 89% CH2Cl2) to yield a white foamy solid 
(312 mg, 72%). 
Data for 92a. Rf = 0.21 (15% MeOH/CH2Cl2). IR (thin film) 3342, 3287, 2924, 
2856, 1493, 1441, 1375, 1260, 1210, 1123, 1035, 1009 cm-1. 1H NMR (300 MHz, CDCl3) 
δ 6.76 (1H, d, J = 8.2 Hz), 6.68 (1H, d, J = 8.2 Hz), 5.89 (1H, dt, J’s  = 10.4, 2.2 Hz), 
5.63 (1H, dt, J = 10.2, 1.6 Hz), 5.39 (1H, dd, J’s  = 4, 2 Hz), 4.42-4.38 (1H, m), 3.87 (3H, 
s), 3.70-3.63 (1H, m), 3.26 (1H, q, J  = 5 Hz), 2.97 (1H, dd, J’s  = 15, 4 Hz), 2.48 (1H, 
dd, J’s = 13.5, 2 Hz), 2.40 (2H, m), 1.98 (2H, dd, J’s = 13.4, 4 Hz), 1.93-1.86 (3H, m), 
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1.58 (1H, m), 1.21 (3H, t, J = 7 Hz). 13C NMR (100 MHz, CDCl3) δ 147.4, 140.5, 135.9, 
128.2, 127.2, 125.6, 120.8, 110.4, 97.7, 64.4, 64.2, 56.1, 50.5, 49.8, 42.2, 38.4, 34.7, 33.2, 
15.2. HRMS calcd. for C19H26NO4 (MH
+) 332.1859, found  332.1856. 
Data for 92b. Rf = 0.26 (15% MeOH/CH2Cl2) IR (thin film) 3352, 3287, 2924, 
1497, 1439 cm-1.1H NMR (400 MHz, CDCl3) δ 6.77 (1H, d, J = 8.3 Hz), 6.65 (1H, d, J = 
8.3 Hz), 5.88 (1H, d, J = 10 Hz), 5.83 (1H, dd, J’s = 10, 4 Hz), 5.50 (1H, dd, J’s = 8, 6 
Hz), 4.12 (1H, d, J = 4 Hz), 4.10 (1H, m), 3.84 (3H, s), 3.67 (1H, m), 3.41 (1H, td, J’s = 
11, 4 Hz), 2.90 (1H, dd, J’s = 15.5, 4.5 Hz), 2.61-2.54 (5H, m), 2.38 (1H, dd, J’s = 15.5 
,2.4 Hz), 2.13 (1H, ddd, J’s = 15.5, 5, 3 Hz), 1.65 (1H, d, J = 10 Hz), 1.59 (1H, dd, J’s = 
13, 8.3 Hz), 1.21 (3H, t, J = 7.3 Hz). 13C NMR (100 MHz, CDCl3) δ 147.8, 141.7, 133.2, 



























To a solution of the primary amines 92a/92b (1.0 g, 3.02 mM) in dioxane (48 mL) 
was added 1N HCl (16 mL) and stirred for 10 min. NaCNBH3 (569 mg, 9.06 mM) was 
added in 3 portions after every 1 h. The mixture was taken to reflux and heated at reflux 
for 5 h. The pH was maintained between 2-3 by adding 1N HCl as required. The reaction 
was checked for completion, judged by TLC, cooled to r.t. and basified to pH 9 with 1M 
NaOH (aq.) and extracted with diethyl ether (5 x 25 mL). The combined organics were 
washed with brine (30 mL), dried (Na2SO4) and conc. in vacuo to yield a brown syrup 
(730 mg). The crude product was purified by column chromatography only for the 
purpose of characterization (SiO2, 1% NEt3, 10% MeOH, 89% CH2Cl2) to yield pure 93 
as a colorless syrup (540 mg, 66% yield).  
Rf = 0.12 (15% MeOH/CH2Cl2). IR (thin film) 3307, 3024, 2920, 2847, 1634, 
1504, 1439, 1278, 1256 cm-1. 1H NMR (300 MHz, CDCl3) δ 6.71 (1H, d, J = 8 Hz), 6.30 
(1H, d, J = 8 Hz), 5.86 (1H, m), 5.71 (1H, m), 4.93 (1H, s), 3.86 (3H, s), 3.43 (1H, m), 
3.00 (1H, dd, J’s = 12, 6 Hz), 2.84 (2H, m), 2.76 (1H, d, J = 18 Hz), 2.35 (1H, m), 1.96 
(1H, t, J = 6 Hz), 1.90 (1H, t, J = 6 Hz), 1.80 (1H, m), 1.45 (1H, m). 13C NMR (75 MHz, 
CDCl3) δ 144.6, 143.1, 131.9, 129.5, 127.1, 124.5, 118.4, 112.7, 87.7, 56.1, 51.9, 49.9, 
41.5, 39.1, 38.8, 30.7, 24.4. HRMS calcd. for C17H20NO2 (MH















To a solution of the secondary amine 93 (0.70 g, 2.6 mmol) in CH2Cl2 (20 ml) 
cooled to 0 °C was added triethylamine (1.81 mL, 13.0 mmol) and ethyl chloroformate 
(0.62 mL, 6.5 mmol) dropwise over 2 min. The resulting solution was stirred at 0 °C for 1 
hour. After checking for completion by TLC, the reaction mixture was quenched with 
saturated aqueous NH4Cl (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined 
extracts were washed with brine (25 mL), dried (Na2SO4) and evaporated in vacuo to 
give a pale yellow oil. The crude product can be purified by column chromatography 
(SiO2, 30% EtOAc/hexanes) to yield 94 as colorless syrup (0.795 g, 90% yield).  
Rf = 0.48 (30% EtOAc/hexanes). IR (thin film) 2978, 2931, 2838, 1695 cm
-1. 1H 
NMR (300 MHz, CDCl3) δ 6.73 (1H, d, J = 8 Hz), 6.62 (1H, d, J = 8 Hz), 5.85 (1H, m), 
5.71 (1H, d, J = 10 Hz)), 4.95 (1H, s), 4.71 (major amide rotamer 0.60 H, bs), 4.56 
(minor amide rotamer 0.4 H, bs), 4.15 (2H, q, J = 7.2 Hz), 4.1-3.93 (1H, m), 3.85 (3H, s), 
3.06-2.86 (2H, m), 2.68 (1H, d, J = 18 Hz), 2.30-2.25 (1H, m), 2.00 (1H, dt, J’s = 18, 6 
Hz), 1.90-1.70 (2H, m), 1.53-1.40 (1H, m), 1.27 (3H, t, J = 7.2 Hz). 13C NMR (75 MHz, 
CDCl3) Major rotamer: δ155.4, 144.9, 143.4, 131.9, 128.5, 125.8, 124.4, 118.9, 113.3, 
87.4, 61.4, 56.2, 50.1, 41.1, 37.7, 35.0, 28.8, 24.0, 14.7. Minor rotamer: δ 155.0, 144.8, 
143.4, 131.6, 128.5, 125.6, 124.6, 118.9, 113.3, 87.4, 61.4, 56.2, 50.5, 41.1, 37.7, 34.8, 
29.0, 24.1, 14.6. HRMS calcd. for C20H24NO4 (MH
+) 342.1705, found 360.1699. Data 
compared with identical compound reported by Taber.5 
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To a solution of 94 (250 mg, 0.73 mmol) in acetone/H2O (10:1, 11 mL) was 
added recrystallized 2,2 bromo-3,5 dimethylhydantoin (520 mg, 1.83 mmol) in small 
portions over 5 min. The entire set-up was covered with aluminum foil, placed in the dark 
and stirred for 12 h until all the starting material was consumed, as judged by TLC. The 
reaction mixture was quenched with saturated NH4Cl (10 ml), diluted with water (10 ml) 
and extracted with ethyl acetate (3 x 15 ml). The combined extracts were washed with 
brine (20 mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The crude 
product can be purified by column chromatography (SiO2, 50 % EtOAc/hexanes) to yield 
99 as colorless syrup (365 mg, 97%), or 99 can be carried forward into the next step 
without purification.  
Rf = 0.26 (1:1 EtOAc/hexanes). IR (thin film) 3420, 2978, 2937, 2889, 1684 cm
-1. 
1H NMR (300 MHz, CDCl3) δ 6.98 (1H, s), 4.83 (1H, d, J = 7 Hz), 4.78 (Major rotamer 
0.60 H, bs), 4.63 (Minor rotamer 0.4 H, bs), 4.11 (2H, q, J = 7.2 Hz), 4.1-3.94 (1H, m), 
3.89 (3H, s), 3.72-2.59 (2H, m), 2.77-2.61 (1H, m), 2.52 (1H, bs), 2.00 (1H, dt, J’s = 17, 
3.7 Hz), 2.20 (1H, m), 1.75-1.70 (1H, m), 1.27 (3H, t, J = 7.2 Hz); 1.07-0.95 ( 1H, m). 
13C NMR (75 MHz, CDCl3) Major rotamer: δ155.4, 145.1, 143.3, 129.3, 125.2, 117.7, 
113.5, 95.8, 70.5, 61.8, 60.4, 56.8, 50.2, 45.4, 38.4, 37.8, 34.4, 31.9, 29.8, 14.6. Minor 
rotamer: δ 155.0, 145.1, 143.3, 129.3, 125.2, 117.7, 113.5, 95.8, 70.2, 61.7, 60.4, 56.8, 
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50.6, 45.4, 38.3, 38.2, 34.1, 31.9, 30.1, 14.7.  HRMS calcd. for C20H24NO4Br2 (MH
+) 










































To a solution of the bromohydrin 99 (365 mg, 0.71 mM) in toluene (15 mL) was 
added solid KOH (200 mg) and the mixture was heated at 80 °C for 3 hours until all the 
starting material was consumed, as judged by TLC. The reaction mixture was cooled and 
diluted with water (15 ml) and extracted with ethyl acetate (3 x 20 mL). The combined 
organics were washed with brine (10 mL), dried (Na2SO4) and conc. in vacuo to give a 
yellow oil. The crude product was purified by column chromatography (SiO2, 40 % 
EtOAc/hexanes) to yield 100 as a colorless syrup (295 mg, 96%).  
Rf = 0.37 (1:1 EtOAc/hexanes). IR (thin film) 2963, 2926, 2850, 1695, 1684 cm
-1. 
1H NMR (300 MHz, CDCl3) δ 6.91 (1H, s), 4.87 (1H, d, J = 3.7 Hz), 4.70 (major amide 
rotamer 0.70 H, bs), 4.56 (minor amide rotamer 0.3 H, bs), 4.13 (2H, q, J = 7.3 Hz), 4.1-
3.89 (1H, m), 3.86 (3H, s), 3.30-2.23 (2H, m), 2.79-2.70 (2H, m), 2.53 (1H, d, J = 18 
Hz), 2.00 (2H, m), 1.79-1.68 (2H, m), 1.27 (3H, t, J = 7.2 Hz); 1.15-1.06 ( 1H, m). 13C 
NMR (75 MHz, CDCl3) Major rotamer: δ155.2, 146.1, 142.9, 129.2, 124.2, 116.7, 112.0, 
87.6, 61.4, 56.4, 53.5, 50.9, 49.8, 41.1, 37.3, 36.2, 35.9, 29.9, 22.7, 14.5. Minor rotamer: 
δ 154.8, 146.1, 142.9, 129.2, 124.0, 116.7, 112.0, 87.6, 61.5, 56.5, 53.5, 50.9, 50.2, 41.1, 
37.2, 36.3, 35.9, 30.2, 22.9, 14.6. HRMS calcd. for C20H23BrNO5 (MH





Alternative Procedure to obtain the epoxide 100.  
To a solution of the carbamate 94 (70 mg, 0.205 mM) in 1,4 dioxane (3 mL) and 
water (1 mL) was added recrystallized 1,3 bromo-5,5 dimethyl hydantoin (60.0 mg, 0.21 
mM) and stirred for 12h in the dark. After 94 was consumed, as judged by TLC, solid 
KOH (50 mg) was added and the solution was heated at 80 °C for 2.5 h. After all the 
intermediate bromohydrin 99 was consumed, as judged by TLC, the solution was diluted 
with water (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organics 
were washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo to give a pale 
yellow oil. The crude product was purified by column chromatography (SiO2, 40% 


































To a solution of the ethylcarbamate 94 (50 mg, 0.12 mM) in acetic acid (1 mL), 
was added 1,3-dibromo-5,5-dimethylhydantoin (17 mg, 0.06 mM) and the solution was 
stirred in the dark for 12h at room temperature. After complete consumption of starting 
material , as judged by TLC, the reaction mixture was poured into water (20 mL) and 
extracted with ethyl acetate (3 x 10 mL). the combined organics were washed with 
saturated NaHCO3 (10 mL), brine (10 mL), dried (Na2SO4) and concentrated in vacuo to 
give a pale yellow liquid. The crude product was purified using flash column 
chromatography (SiO2, 30% EtOAc/Hexanes) to give pure 102 as a colorless crystalline 
solid upon standing (59 mg, 89% yield).  
Rf = 0.31 (7:3 Hexanes/EtOAc). M. P. = 112-115 °C. IR (thin film) 2975, 2938, 
1740, 1690, 1653, 1489, 1430, 1374, 1226, 1143, 1040 cm-1. 1H NMR (300 MHz, CDCl3) 
δ 6.98 (1H, s), 4.91 (1H, m), 4.85 (1H, d, J = 7.4 Hz), 4.77 (Major rotamer 0.60 H, bs), 
4.61 (Minor rotamer 0.4 H, bs), 4.16 (2H, m), 4.11-3.91 (1H, m), 3.89 (3H, s), 3.65 (1H, 
dd, J = 11.3, 7.4 Hz), 2.73-2.63 (2H, m), 2.23 (1H, dt, J’s = 12, 4 Hz), 2.02 (3H, s), 1.98 
(1H, d, J = 13 Hz), 1.75-1.63 (2H, m), 1.27 (3H, m), 1.03 (1H, q, J = 12 Hz). 13C NMR 
(75 MHz, CDCl3) Major rotamer: δ 169.6, 155.3, 145.1, 143.3, 129.2, 125.1, 117.8, 
113.5, 95.9, 71.2, 61.7, 61.6, 56.8, 54.1, 50.0, 45.1, 38.1, 37.7, 34.4, 30.7, 20.8, 14.6. 
Minor rotamer: δ 169.8, 154.9, 145.1, 143.3, 129.2, 124.8, 117.8, 113.4, 95.9, 71.4, 61.8, 
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61.6, 56.8, 53.9, 50.4, 45.1, 38.0, 37.7, 34.1, 30.7, 20.8, 14.7. HRMS calcd. for 
C22H26NO6Br2 (MH


















































To a solution of diphenyl disulfide (12 mg, 0.055 mmol) in EtOH (1.0 mL) was 
added NaBH4 (4 mg, 0.11 mmol) portion-wise over 5 min. The resulting solution was 
stirred for 15 min and then added drop-wise to a solution of the epoxide 100 (16 mg, 
0.037 mmol) in EtOH (1.0 mL). The reaction mixture was stirred at 25 °C for 2 h until all 
the substrate was consumed, as judged by TLC. The mixture was diluted with water (5 
mL) and extracted with CH2Cl2 (3 x 5 mL). The combined organics were washed with 
brine (5 mL), dried (Na2SO4) and conc. in vacuo to give a pale yellow solid. The crude 
product was purified by column chromatography (SiO2, 30% EtOAc/hexanes) to yield 
106 as a white solid (20 mg, 99% yield).  
Rf = 0.60 (40% EtOAc/hexanes). IR (thin film) 3446, 2936, 1684, 1487, 1437 cm
-
1. 1H NMR (300 MHz, CDCl3) δ 7.39 (2H, d, J = 7.3 Hz), 7.30 (3H, m), 6.93 (1H, s), 4.88 
(1H, d, J = 5 Hz), 4.69 (Major rotamer 0.60 H, bs), 4.54 (Minor rotamer 0.4 H, bs), 4.14 
(2H, q, J = 7.2 Hz), 4.07-3.91 (2H, m), 3.84 (3H, s), 3.36-3.28 (1H, m), 2.79-2.59 (2H, 
m), 2.39-2.34 (2H, m), 1.85-1.56 (4H, m), 1.27 (3H, t, J = 7.2 Hz); 13C NMR (75 MHz, 
CDCl3) Major rotamer: δ155.3, 145.8, 142.8, 132.3, 129.2, 127.7, 125.1, 116.6, 112.8, 
89.0, 68.4, 61.5, 60.3, 56.4, 50.5, 46.5, 42.5, 37.6, 36.2, 36.0, 29.9, 24.4, 21.0, 14.6; 
Minor rotamer: δ 155.0, 145.8, 142.8, 133.2, 132.0, 130.7, 129.2, 127.7, 124.8, 116.6, 
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112.8, 89.0, 68.4, 61.6, 56.4, 51.0, 46.5, 42.3, 37.6, 36.4, 35.7, 30.1, 24.4, 14.7; HRMS 
calcd. for C26H29BrNO5S (MH















Procedure is the same as that used for the phenylsulfide 106, except 
diphenyldiselenide is used in this case. Yield (93%). 
Rf = 0.32 (40% EtOAc/hexanes). IR (thin film) 3447, 2917, 2849, 1695, 1684, 
1489, 1437, 1319, 1289, 1228 cm-1. 1H NMR (300 MHz, CDCl3)  7.53 (2H, d, J = 6.6 
Hz), 7.30 (3H, m), 6.94 (1H, s), 4.95 (1H, d, J = 5.2 Hz), 4.70 (Major rotamer 0.60 H, 
bs), 4.55 (Minor rotamer 0.4 H, bs), 4.16 (2H, q, J = 7.0 Hz), 4.03-3.98 (2H, m), 3.86 
(3H, s), 3.36-3.28 (1H, m), 2.80-2.70 (2H, m), 2.63 (1H, d, J = 18 Hz), 2.29 (2H, m), 
1.85-1.75 (2H, m), 1.66-1.55 (2H, m), 1.27 (3H, t, J = 7.2 Hz). HRMS calcd. for 











































To a solution of 106 (20 mg, 0.036 mmol) in hexafluoroisopropanol (0.5 mL) was 
added hydrogen peroxide (30% aq., 0.05mL) and the resulting solution was stirred for 15 
min until all starting material was consumed, as judged by TLC. The reaction mixture 
was diluted with water (5 ml) and quenched with saturated aqueous Na2SO3 (2 mL) and 
the two phases were separated. The aqueous layer was extracted with CH2Cl2 (2 x 5 mL) 
and the combined extracts were washed with brine (5 mL), dried (Na2SO4) and conc. in 
vacuo to give a pale yellow solid. The crude product (107) was dissolved in toluene (2 
mL) and solid NaHCO3 (15 mg) was added. The mixture was heated at reflux for 2 h 
until all the intermediate sulfoxide had been consumed. The reaction was diluted with 
water (10 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined extracts were 
washed with brine (5 mL), dried (Na2SO4) and conc. in vacuo to give a pale yellow 
syrup. The crude product was purified by column chromatography (SiO2, 50% 
EtOAc/hexanes) to yield a colorless syrup (14 mg) as a mixture of 101 (76 % yield) along 
with the saturated ketone 108 (17%). 
Rf = 0.60 (40% EtOAc/Hexanes). IR (thin film) 3446, 2978, 2932, 2868, 1684, 
1489, 1435 cm-1. 1H NMR (300 MHz, CDCl3) δ 6.94 (1H, s), 5.77 (1H, d, J = 8.8 Hz), 
5.30 (1H, dd, J = 6.6, 1.5 Hz), 5.02 (Major rotamer 0.60 H, bs), 4.90 (1H, d, J = 6.6 Hz), 
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4.88 (Minor rotamer 0.4 H, bs), 4.14 (2H, q, J = 7.2 Hz), 3.84 (3H, s), 2.96-2.84 (2H, m), 
2.78-2.66 (3H, m), 2.60-2.52 (1H, d, J = 21 Hz), 2.45-2.41 (1H, m), 1.95-1.87 (4H, m), 
1.27 (3H, t, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) Major rotamer: δ155.4, 145.9, 
143.3, 134.4, 131.3, 126.9, 125.5, 116.2, 113.3, 91.4, 66.0, 56.4, 50.3, 47.8, 43.8, 39.3, 
37.2, 35.3, 29.7, 14.6; Minor rotamer: δ 155.0, 145.9, 143.3, 134.7, 131.3, 126.8, 125.3, 
117.7, 113.5, 91.4, 61.7, 56.8, 49.9, 47.8, 41.1, 39.7, 37.7, 34.9, 29.9, 14.7. HRMS calcd. 
for C20H22BrNO5Na (M+Na
+) 458.0579, found 458.0577.  
The minor product corresponding to the saturated ketone 108 can be identified by 
the following signals. Rf = 0.61 (40% EtOAc/Hexanes). IR (thin film) 1732 cm
-1. 1H 
NMR (300 MHz, CDCl3) δ 6.95 (0.23 H, s), 4.60 (0.23 H, s). 
13C NMR (75 MHz, CDCl3) 
δ 206.5. HRMS calcd. for C20H23BrNO5 (MH


























































To a solution of the selenide 104 (25 mg, 42 µM) in THF (2.0 mL) and saturated 
aqueous NaHCO3 (2 mL) was added a solution of NaIO4 (225 mg) in H2O (1 mL) in a 
single portion. The mixture was stirred for 45 min and then filtered over Celite® and 
washed repeatedly with DCM. The combined organics were washed with brine (5 mL), 
dried (Na2SO4) and concentrated in vacuo. The resulting solid (105) was dissolved in 
benzene (5 mL) and saturated aqueous NaHCO3 (1 mL) and heated at reflux for 1 h until 
all the intermediate had been consumed, as judged by TLC. The mixture was diluted with 
water and extracted with CH2Cl2 (3 x 10 ml) and  the organic layers were separated. The 
combined organic layers were washed were washed with brine (5 mL), dried (Na2SO4) 
and concentrated in vacuo to give a colorless oil. The crude product was purified by 
column chromatography (SiO2, 50% EtOAc/hexanes) to yield 101 as a colorless syrup 
















To the allylic alcohol 101 (10 mg, 0.023 mM), in THF (1.5 mL) was added 
LiAlH4 (2M in THF, 0.3 mL) and the solution was stirred at 25 °C for 6 h. The reaction 
mixture was cooled to 0 °C and quenched with drop-wise addition of saturated aqueous 
Na2SO4 (0.5 mL). The salts were filtered over a pad of Celite and washed with diethyl 
ether (10 mL). The combined organics were dried (Na2SO4) and evaporated in vacuo to 
yield a pale yellow solid. The crude product was purified (SiO2, 10% MeOH/CH2Cl2) to 
give codeine 3 (6 mg, 87%).  
Rf = 0.21 (10% MeOH/CH2Cl2). M.p. 151-153 °C. IR (thin film) 3283, 2962, 
2917, 2851, 1506, 1456, 1472, 1261, 1089, 1048, 1020 cm-1. 1H NMR (300 MHz, CDCl3) 
δ 6.66 (1H, d, J = 8.1 Hz), 6.57 (1H, d, J = 8.8 Hz), 5.71 (1H, d, J = 9.5 Hz), 5.30 (1H, 
dt, J = 10.3, 2.2 Hz), 4.90 (1H, dd, J = 6.6 Hz), 4.19 (1H, m), 3.85 (3H, s), 3.36 (1H, dd, J 
=  6, 3 Hz), 3.06 (1H, d, J = 19.1 Hz), 2.69 (1H, s), 2.60 (1H, dd, J = 12.5, 3.7 Hz), 2.45 
(3H, s), 2.39 (1H, dd, J = 12.5, 3.7 Hz), 2.31 (1H, dd, J = 18.4, 5.9 Hz), 2.03-2.12 (1H, 
m), 1.86-1.90 (1H, m), 1.26 (1H, bs); 13C NMR (100 MHz, CDCl3) δ 146.2, 142.2, 133.4, 
131.0, 128.2, 127.2, 119.5, 112.8, 91.3, 66.4, 58.8, 56.3, 46.4, 43.1, 40.7, 35.8, 29.8, 20.3. 















To a solution of codeine 3 (8 mg, 0.026 mM) in chloroform (2.5 mL), was added 
boron tribromide (1.0 M in DCM, 0.20 mmol) dropwise over 1 min and the resulting 
mixture was stirred at room temperature for 20 min. A solution of NH4OH (10 % aq., 10 
mL) was added dropwise at 0 °C and the mixture was extracted with a solution of 9:1 
DCM/EtOH (4 x 15 mL). The combined organics were washed with brine (25 mL), dried 
(Na2SO4) and concentrated in vacuo. The crude product was purified (SiO2, 1:9 
MeOH/DCM) to give morphine 1 (6.5 mg, 86% yield) as a white solid. Rf = 0.06 (1:9 
MeOH/DCM). M.p. 251-255 °C. IR (thin film) 3352, 2924, 1459, 1249 cm-1. 1H NMR 
(300 MHz, CDC13) δ 6.62 (1H, d, J = 8.1 Hz), 6.48 (1H, d, J = 8.1 Hz), 5.67 (1H, d, J = 
9.9 Hz), 5.27 (1H, dt, J = 9.9, 2.6 Hz), 4.84 (1H, dd, J = 6.3 Hz), 4.18 (1H, m), 3.84 (3H, 
s), 3.36 (1H, m), 3.03 (1H, d, J = 18.6 Hz), 2.66 (1H, m), 2.60 (1H, d, J = 4.5 Hz), 2.47 
(1H, dd, J = 24.3, 3.6 Hz), 2.46 (1H, s), 2.34 (1H, dd, J = 18.9, 6.3 Hz), 2.06 (1H, dt, J = 
12.9, 5.1 Hz), 1.90 (1H, d, J = 12.9 Hz). 13C NMR (75 MHz, CDC13) δ 145.6, 138.1, 
132.7, 130.4, 127.9, 125.5, 119.5, 116.8, 91.1, 66.2, 58.7, 46.2, 42.7, 42.4, 40.0, 34.8, 
20.4. HRMS calcd, for C17H20NO3 (MH








4.2 EXPERIMENTAL CONDITIONS AND COMPOUND DATA FOR CHAPTER 2 
 
 
















To nitromethane (0.04 mL) in THF (0.5 mL) at -78 °C under argon, was added n-
butyllithium (0.03 mL, 2.5 M in hexanes) and the mixture was stirred for 15 min. To this 
slurry, a solution of the dienone 60 (25 mg, 0.08 mM) in THF (0.5 mL) was added drop-
wise over 1 min. The mixture was stirred for an additional 30 h at -78 °C after which all 
the starting material had been consumed, as judged by TLC. The reaction mixture was 
quenched with saturated NH4Cl (2 mL) and extracted with ether. Flash column 
chromatography (SiO2, 30% EtOAc/Hexanes) separated the two compounds; each a 
colorless foam (22 mg, 74% combined yield).   
 
Data for 119a: Rf = 0.20 (1:1 EtOAc/hexanes). 
1H NMR (300 MHz, CDCl3) δ 7.54 (1H, 
dd, J’s = 10, 3 Hz), 7.20 (1H, d, J = 9 Hz), 6.99 (1H, J’s = 10, 3 Hz), 6.96 (1H, d, J = 9 
Hz), 6.46 (1H, dd, J’s = 8, 2 Hz), 6.30 (1H, dd, J’s = 8, 2 Hz), 5.51 (1H, d, J = 12 Hz), 
5.46 (1H, t, J = 2 Hz), 4.46 (1H, dd, J’s = 18, 12 Hz), 4.21 (1H, dd, J’s = 18, 2 Hz), 4.00 
(s, 3H), 3.87 (1H, m), 3.65 (1H, m), 3.04 (1H, bs), 2.38 (1H, dd, J’s = 14, 2 Hz), 1.94 
(1H, dd, J’s = 14, 2 Hz), 1.18 (3H, t, J = 7 Hz).  
 141 
Data for 119b: Rf = 0.25 (1:1 EtOAc/hexanes). 
1H NMR (300 MHz, CDCl3) δ 7.75 (1H, 
dd, J’s = 10, 3 Hz), 7.04 (1H, J’s = 10, 3 Hz), 6.98 (1H, d, J = 9 Hz), 6.38 (1H, dd, J’s = 
8, 2 Hz), 6.36 (1H, dd, J’s = 8, 2 Hz), 5.5 (1H, t, J = 2 Hz), 5.42 (1H, m), 4.60 (1H, t, J = 
18 Hz), 4.52 (1H, dd, J’s = 18, 12 Hz), 4.00 (s, 3H), 3.96 (1H, m), 3.70 (1H, m), 2.89 
(1H, d, J = 14 Hz), 2.21 (1H, dd, J’s = 14, 2 Hz), 1.96 (1H, dd, J’s = 14, 2 Hz), 1.25 (3H, 
t, J = 7 Hz). 
13C NMR could not be obtained due to rapid cyclization of the compounds to the 




































To a solution of the dienone 60 (20 mg, 0.064 mM) in toluene (0.5 mL) at -20 °C, 
was added the phase-transfer catalyst (8S, 9R)-(-)-N-Benzylcinchonidinium chloride 
(M.P. 209 °C)(8mg) followed by flame-dried Cs2CO3 (20 mg, 0.064 mM) and 
nitromethane (0.05 mL, 0.94 mM) and the solution was stirred for 24h until all the 
dienone had been consumed , as judged by TLC. The reaction mixture was diluted with 
ether (5 mL), quenched with saturated NH4Cl (2 mL) and extracted with ether (3 x 5 mL). 
The combined organics were washed with bring (10 mL), dried (Na2SO4) and 
concentrated in vacuo to give a pale yellow solid. The products were purified via column 
chromatography (SiO2, 40% EtOAc/Hexanes) to give the two title compounds as white 
crystalline solids in approximately 1:1 ratio. (Combined: 14.2 mg, 60% yield).  
 
Data for compound 114a:  Rf = 0.37 (1:1 EtOAc/hexanes). M.p. 210 °C. [α]D
24.5= -200.0° 
(c = 1.0 CH2Cl2). IR (thin film) 3481, 2975, 2931, 1675, 1555, 1442, 1344, 1267, 1042 
cm-1. 1H NMR (300 MHz, CDCl3) δ 7.10 (1H, d, J = 8.9 Hz), 6.99 (1H, dd, J’s = 10, 2 
Hz), 6.97 (1H, d, J = 8 Hz), 5.98 (1H, d, J = 10 Hz), 5.56 (1H, t, J = 1.5 Hz), 5.12 (1H, t, 
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J = 6.1 Hz), 5.00 (1H,t, J = 6 Hz), 3.98 (3H, s), 3.92 (1H, m), 3.70 (1H, m), 3.00 (1H, dd, 
J = 18, 5.2 Hz), 2.89 (1H, m), 2.78 (1H, s), 2.74 (1H, d, J = 9 Hz), 2.62 (1H, dd, J’s = 
13.2, 1.5 Hz), 2.23 (1H, dd, J = 13.2, 3 Hz), 1.21 (3H, t, J = 6.6 Hz). 13C NMR (75 MHz, 
CDCl3) δ 192.9, 154.4, 148.6, 139.1, 127.9, 127.6, 120.9, 116.4, 111.2, 95.6, 92.3, 68.7, 
64.4, 60.4, 56.1, 42.2, 40.4, 35.6, 34.9, 29.7, 15.1. HRMS calcd. for C19H20NO7 (M-H
+) 
374.1245, found  375.1243.  
 
Data for compound 114b: Rf = 0.42 (1:1 EtOAc/hexanes). M.p. 188-190 °C. [α]D
25.4= 
+154.9° (c = 1.0 CH2Cl2). IR (thin film) 3420, 2976, 2932, 1683, 1553, 1502, 1440, 
1344, 1279, 1047 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.03 (1H, d, J = 8.1 Hz), 6.96 (1H, 
d, J = 8.8 Hz), 6.79 (1H, dd, J’s = 10.3, 1.5 Hz), 6.06 (1H, d, J = 10.3 Hz), 5.53 (1H, dd, 
J = 8.1, 6.6 Hz), 5.15 (1H, d, J = 2.2 Hz), 4.93 (1H, dd, J = 12, 3 Hz), 4.09 (1H, m), 3.89 
(3H, s), 3.69 (1H, m), 2.92 (1H, ddd, J = 12, 5.2, 2.2 Hz), 2.99-2.85 (3H, m), 2.74 (1H, d, 
J = 18 Hz), 2.05 (1H, dd, J’s = 13.2, 8.1Hz), 1.21 (3H, t, J = 6.6 Hz). 13C NMR (75 MHz, 
CDCl3) δ 192.9, 154.4, 148.6, 139.1, 127.9, 127.6, 120.9, 116.4, 111.2, 95.6, 92.3, 68.7, 










4.3 EXPERIMENTAL CONDITIONS AND COMPOUND DATA FOR CHAPTER 3 
 
 









To a solution of the dienone 60 (100 mg, 0.32 mM) in 1,4-dioxane (1.5 mL) was 
added methylamine hydrochloride (25.8 mg, 0.38 mM) followed by N,N-
diisopropylethylamine (0.07 mL, 0.38 mM) and the solution was stirred at 0 °C for 1h. 
Sodium cyanoborohydride (30 mg, 0.48 mM) was then added, in small portions, and the 
solution was stirred for an additional 12h. The reaction mixture was poured into saturated 
NaHCO3 solution (10 mL) and extracted with ether (4 x 10 mL). The combined organics 
were washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo to give a 
colorless syrup. Purification by column chromatography (SiO2, 50% EtOAc/Hexanes) 
gave pure 129a/129b as an inseparable mixture of two diastereomers (86 mg, 82% yield).  
Rf 0.37 (1:1 hexanes/EtOAc); IR (thin film) 3364, 2925, 2853, 2784, 1684 cm-1; 
1H NMR (300 MHz, CDCl3) δ 6.82 (2H, t, J = 9 Hz), 6.65 (1H, d, J = 8 Hz), 6.03 (1H, d, 
J = 10 Hz), 5.54 (1H, t, J = 7 Hz), 4.14-4.07 (1H, m), 3.85 (3H, s), 3.71-3.65 (1H, m), 
3.40 (1H, d, J = 15 Hz), 2.85 (1H, dd, J = 5, 3 Hz), 2.78 (1H, d, J = 5 Hz), 2.72-2.66 (2H, 
m), 2.37 (3H, s), 1.88 (1H, d, J = 13 Hz), 1.86 (1H, d, J = 13 Hz), 1.23 (3H, t, J = 7 Hz); 
13C NMR (75 MHz, CDCl3) δ 196.8, 151.8, 147.6, 127.9, 125.4, 125.0, 118.5, 111.8, 
110.8, 98.7, 66.2, 64.1, 57.5, 56.1, 41.8, 40.6, 37.7, 29.5, 14.8; HRMS calcd. for 
C19H24NO4 (MH
+) 330.1705, Found 330.1704. 
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1,4-Dioxane (1.5 mL), 1.0 M aqueous HCl (1.5 mL), and the cross-conjugated 
dienone 60 (0.080 g, 0.255 mmol) were stirred at 23 °C for 1 h until the mixture was 
homogeneous.  The solution was heated for 2 h at reflux until all starting material was 
consumed, as judged by TLC. The mixture was poured into water (30 mL) and extracted 
with EtOAc (3 x 15 mL). The combined organics were washed with brine (30 mL), dried 
(Na2SO4), and concentrated in vacuo to yield 131 as pale yellow-orange foam (0.072 g, 
93% yield). Crystallization of 131 from MeCN with slow cooling provided X-ray quality 
crystals for the purpose of characterization.  
Rf 0.28 (1:1 hexanes/EtOAc). M.p. 212 °C. IR (thin film) 3461, 2934, 2908, 2844, 
1719, 1679 cm-1. 1H NMR (300 MHz, CDCl3) δ 9.82 (1H, s), 7.56 (1H, d, J = 8 Hz), 7.03 
(1H, d, J = 8 Hz), 6.19 (1H, d, J = 9 Hz), 5.65 (1H, t, J = 7 Hz), 4.71 (1H, d, J = 64 Hz), 
4.00 (3H, s), 3.08-2.99 (2H, m), 2.81 (1H, dd, J = 41, 3 Hz), 2.80 (1H, dd, J’s = 6 and 3 
Hz), 2.34-2.22 (2H, m). 13C NMR (75 MHz, CDCl3) δ 204.8, 192.3, 150.4, 149.4, 133.4, 
132.2, 129.5, 125.7, 111.3, 98.1, 89.9, 56.2, 53.7, 46.7, 39.0, 38.1. HRMS calcd. for 
C16H15O5 (MH
+ – H2O) 287.0919, found 287.0924. Structure of 131 by X-ray shows that 















To a solution of the lactol 131 (500 mg, 1.64 mM) in 1,4-dioxane (8 mL) was 
added recrystallized methylamine hydrochloride (133 mg, 1.97 mM) followed by N,N-
diisopropylethylamine (0.43 mL, 2.46 mM) and the resulting suspension was stirred in a 
sealed flask for 8 h at r.t. Glacial acetic acid (0.94 mL, 24.6 mM) followed by NaBH3CN 
was then added and the suspension  was stirred until a single spot was seen on the TLC. 
The reaction mixture was carefully quenched with aqueous satd. NaHCO3. The aqueous 
layer was extracted with chloroform (4 x 25 mL) and the combined organics were washed 
with brine (20 mL), dried (Na2SO4) and concentrated in vacuo to yield a pale brown solid 
(448 mg, 80% yield). NMR indicated that the crude material was pure enough to be used 
without further purification. However, material of very high purity can be obtained by 
flash column chromatography (SiO2, 10 % MeOH/CHCl3). The compound 132a was 
crystallized from toluene and the structure was elucidated by X-ray crystallography.  
Rf = 0.43 (9:1 CHCl3/MeOH). M.p. 202 °C. IR (thin film) 3420, 2923, 2847, 
2414, 1718, 1507, 1437, 1286 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.66 (1H, d, J  = 8.2 
Hz)), 6.60 (1H, d, J = 8.2 Hz), 6.02 (1H, dd, J’s = 10.4, 0.5 Hz), 5.20 (1H, d, J = 3.7 Hz), 
4.68 (1H, t, J = 3 Hz), 4.41 (1H, d, J = 15 Hz), 4.33 (1H, s), 3.86 (1H, d, J = 15 Hz), 3.77 
(3H, s), 3.66 (1H, t, J = 14 Hz), 3.26 (1H, d, J = 15 Hz), 2.89 (1H, dd, J’s = 18, 3 Hz), 
2.84 (1H, dd, J’s = 18, 3 Hz), 2.50 (1H, dd, J’s = 17.2, 4 Hz), 2.38 (3H, s), 2.34 (1H, d, J 
 147 
= 3), 2.14 (1H, dd, J’s = 17, 1.4), 1.92 (1H, t, J = 13.1 Hz)  13C NMR (100 MHz, CDCl3 
+ 5% DMSO-d6) δ 206.8, 146.9, 145.2, 131.1, 124.3, 121.0, 111.9, 88.1, 
65.6, 63.5, 59.3, 55.7, 50.3, 43.4, 42.3, 29.5.HRMS calcd. for C18H23BN2O4 (MH
+) 































To a solution of the crude β-hydroxyketone 132a (448 mg, 1.47 mM) in 1,4-
dioxane (5 mL) was added a 20% solution of methanesulfonic acid in water (0.5 mL). 
The solution was heated at reflux for 4 h until complete conversion to Narwedine was 
observed, as judged by TLC. The reaction mixture was cooled to r.t. and quenched with 
saturated aqueous NaHCO3 to pH ~ 8.5. The aqueous layer was extracted with CHCl3 (4 
x 20 mL) and the combined organics were washed with brine (20 mL), dried (Na2SO4) 
and concentrated in vacuo to a give (±)-narwedine 56 as a pale brown solid. (338 mg, 
88% yield).  
Rf 0.35 (9:1 CHCl3/MeOH). M.p. 186 °C. IR (thin film) 2924, 2853, 1683, 1506, 
1436, 1283 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.94 (1H, dd, J’s  = 10.4, 1.4 Hz)), 6.69 
(1H, d, J = 8.2 Hz), 6.62 (1H, d, J = 8.2 Hz), 6.02 (1H, dd, J’s = 10.4, 0.5 Hz), 4.72 (1H, 
m), 4.07 (1H, d, J = 15.5 Hz), 3.82 (3H, s), 3.73 (1H, d, J = 15.5 Hz), 3.26-3.10 (3H, m), 
2.74 (1H, dd, J’s = 17.7, 4 Hz), 2.43 (3H, s), 2.26 (1H, td, J’s = 13.7 and 3.5 Hz ), 1.84 
(1H, ddd, J’s = 13.7, 3.5, 2.0 Hz). 13C NMR (100 MHz, CDCl3) 
δ 194.4, 146.9, 144.3, 143.9, 130.5, 129.3, 127.0, 121.9, 111.7, 87.9, 60.6, 55.9, 54.0, 48.
9, 42.4, 37.2, 33.2. HRMS calcd. for C17H20NO3 (MH
+) 286.1443, found 286.1441.  
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Appendix A: X-ray Data for the nitroalkene 80a 
 
 
Figure 1.  View of the nitroalkene 80a showing the atom labeling scheme.  Displacement 











X-ray Experimental for nitroalkene 80a 
Crystals grew as yellow laths by slow evaporation from dichloromethane and 
hexanes.  The data crystal was cut from a cluster of crystals and had approximate 
dimensions; 0.15 x 0.11 x 0.10 mm.  The data were collected on a Nonius Kappa CCD 
diffractometer using a graphite monochromator with MoKα radiation (λ = 0.71073Å).  A 
total of 199 frames of data were collected using ω-scans with a scan range of 2° and a 
counting time of 226 seconds per frame.  The data were collected at 153 K using an 
Oxford Cryostream low temperature device.  Details of crystal data, data collection and 
structure refinement are listed in Table 1.  Data reduction were performed using DENZO-
SMN.1  The structure was solved by direct methods using SIR972 and refined by full-
matrix least-squares on F2 with anisotropic displacement parameters for the non-H atoms 
using SHELXL-97.3  The hydrogen atoms on carbon were calculated in ideal positions 
with isotropic displacement parameters set to 1.2xUeq of the attached atom (1.5xUeq for 
methyl hydrogen atoms).  The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 
1/[(σ(Fo))2 + (0.0395*P)2 + (0.6162*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 
0.131, with R(F) equal to 0.0564 and a goodness of fit, S, = 1.02.  Definitions used for 
calculating R(F), Rw(F2) and the goodness of fit, S, are given below.4  The data were 
corrected for secondary extinction effects.  The correction takes the form:  Fcorr = kFc/[1 
+ (7.4(10)x10-6)* Fc2 λ3/(sin2θ)]0.25 where k is the overall scale factor.  Neutral atom 
scattering factors and values used to calculate the linear absorption coefficient are from 
the International Tables for X-ray Crystallography (1992).5  All figures were generated 
using SHELXTL/PC.6  Tables of positional and thermal parameters, bond lengths and 
angles, torsion angles, figures and lists of observed and calculated structure factors are 
located in tables 1 through 7.   
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Table 1.  Crystal data and structure refinement for nitroalkene 80a. 
 
Empirical formula    C19 H19 N O6 
Formula weight    357.35 
Temperature     153(2) K 
Wavelength     0.71073 Å 
Crystal system    Triclinic 
Space group     P-1 
Unit cell dimensions   a = 12.0662(3) Å α= 104.467(2)°. 
     b = 12.3161(3) Å β= 90.041(2)°. 
     c = 13.8006(5) Å γ = 118.668(2)°. 
Volume    1724.78(9) Å3 
Z     4 
Density (calculated)   1.376 Mg/m3 
Absorption coefficient  0.103 mm-1 
F(000)     752 
Crystal size    0.15 x 0.11 x 0.10 mm 
Theta range for data collection 1.94 to 27.50°. 
Index ranges    -15<=h<=15, -15<=k<=15, -14<=l<=17 
Reflections collected   12233 
Independent reflection  7819 [R(int) = 0.0355] 
Completeness to theta = 27.50° 98.9 %  
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  7819 / 0 / 474 
 153 
Goodness-of-fit on F2    1.015 
Final R indices [I>2sigma(I)]   R1 = 0.0564, wR2 = 0.1058 
R indices (all data)    R1 = 0.1257, wR2 = 0.1313 
Extinction coefficient    7.4(10)x10-6 
Largest diff. peak and hole   0.450 and -0.224 e.Å-3 
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 Table 2.  Atomic coordinates (x 10
4











 x y z U(eq) 
________________________________________________________________________ 
O1A 6616(1) 6814(2) 6575(1) 40(1) 
C2A 7097(2) 7522(2) 5843(2) 38(1) 
C3A 8134(2) 8899(2) 6326(2) 35(1) 
C4A 9260(2) 9020(2) 6955(2) 30(1) 
C5A 10030(2) 8549(2) 6287(2) 33(1) 
C6A 11167(2) 9313(2) 6065(2) 39(1) 
C7A 11759(2) 10719(2) 6401(2) 42(1) 
C8A 10909(2) 11224(2) 6861(2) 38(1) 
C9A 10144(2) 10449(2) 7578(2) 31(1) 
C10A 10983(2) 10492(2) 8419(2) 31(1) 
C11A 10669(2) 9536(2) 8834(2) 32(1) 
C12A 9457(2) 8349(2) 8507(2) 29(1) 
C13A 9010(2) 7459(2) 9065(2) 36(1) 
C14A 7799(2) 6385(2) 8782(2) 37(1) 
C15A 7020(2) 6196(2) 7956(2) 36(1) 
C16A 7477(2) 7078(2) 7370(2) 32(1) 
C17A 8692(2) 8134(2) 7630(2) 28(1) 
O18A 7562(2) 6914(1) 5107(1) 39(1) 
C19A 6565(2) 5711(2) 4440(2) 49(1) 
C20A 7152(3) 5290(2) 3578(2) 55(1) 
O21A 12865(2) 11435(2) 6322(2) 64(1) 
N22A 12150(2) 11710(2) 8891(1) 39(1) 
O23A 13035(2) 11688(2) 9316(1) 51(1) 
O24A 12188(2) 12722(2) 8864(1) 47(1) 
O25A 5812(2) 5188(2) 7617(1) 49(1) 
 155 
C26A 5279(3) 4289(3) 8205(2) 64(1) 
O1 7973(1) 2791(1) 3196(1) 37(1) 
C2 7683(2) 2186(2) 2117(2) 39(1) 
C3 6597(2) 818(2) 1839(2) 37(1) 
C4 5387(2) 645(2) 2316(2) 31(1) 
C5 4768(2) 1295(2) 1908(2) 35(1) 
C6 3676(2) 686(2) 1288(2) 39(1) 
C7 2996(2) -724(2) 874(2) 41(1) 
C8 3743(2) -1366(2) 1015(2) 40(1) 
C9 4415(2) -818(2) 2111(2) 34(1) 
C10 3479(2) -1007(2) 2865(2) 33(1) 
C11 3721(2) -186(2) 3778(2) 34(1) 
C12 4935(2) 988(2) 4129(2) 31(1) 
C13 5261(2) 1729(2) 5130(2) 34(1) 
C14 6465(2) 2813(2) 5468(2) 34(1) 
C15 7355(2) 3128(2) 4806(2) 32(1) 
C16 7020(2) 2391(2) 3783(2) 31(1) 
C17 5812(2) 1343(2) 3437(2) 29(1) 
O18 7432(2) 2914(2) 1630(1) 46(1) 
C19 8578(3) 4114(2) 1635(2) 53(1) 
C20 8235(4) 4768(3) 1006(2) 80(1) 
O21 1896(2) -1328(2) 441(1) 59(1) 
N22 2293(2) -2238(2) 2650(2) 43(1) 
O23 1360(2) -2270(2) 3037(2) 59(1) 
O24 2287(2) -3208(2) 2109(1) 53(1) 
O25 8564(2) 4135(1) 5061(1) 39(1) 







Appendix B: X-ray Data for the nitroalkene 80b 
 
Figure 1.  View of nitroalkene 80b showing the atom labeling scheme.  Displacement 













X-ray Experimental for Nitroalkene 80b   
 
Crystals grew as yellow needles by slow evaporation from chloroform.  The data 
crystal was a needle that had approximate dimensions; 0.31 x 0.09 x 0.08 mm.  The data 
were collected on a Nonius Kappa CCD diffractometer using a graphite monochromator 
with MoKα radiation (λ = 0.71073Å).  A total of 238 frames of data were collected using 
ω-scans with a scan range of 1.9° and a counting time of 146 seconds per frame.  The 
data were collected at 153 K using an Oxford Cryostream low temperature device.  
Details of crystal data, data collection and structure refinement are listed in Table 1.  Data 
reduction were performed using DENZO-SMN.1  The structure was solved by direct 
methods using SIR972 and refined by full-matrix least-squares on F2 with anisotropic 
displacement parameters for the non-H atoms using SHELXL-97.3  The hydrogen atoms 
were observed in a ∆F map and refined with isotropic displacement parameters.  The 
function, Σw(|Fo|
2 - |Fc|
2)2, was minimized, where w = 1/[(σ(Fo))
2 + (0.0512*P)2 + 
(0.5475*P)] and P = (|Fo|
2 + 2|Fc|2)/3.  Rw(F
2) refined to 0.116, with R(F) equal to 0.0445 
and a goodness of fit, S, = 1.00.  Definitions used for calculating R(F), Rw(F
2) and the 
goodness of fit, S, are given below.4  The data were corrected for secondary extinction 
effects.  The correction takes the form:  Fcorr = kFc/[1 + (6.1(11)x10
-6)* Fc
2 λ 3/(sin2θ)]0.25 
where k is the overall scale factor.  Neutral atom scattering factors and values used to 
calculate the linear absorption coefficient are from the International Tables for X-ray 
Crystallography (1992).5  All figures were generated using SHELXTL/PC.6  Tables of 
positional and thermal parameters, bond lengths and angles, torsion angles, figures and 




Table 1.  Crystal data and structure refinement for nitroalkene 80b. 
 
Empirical formula    C19 H19 N O6 
Formula weight    357.35 
Temperature     153(2) K 
Wavelength     0.71073 Å 
Crystal system   Monoclinic 
Space group     P21/c 
Unit cell dimensions   a = 8.4748(2) Å α= 90°. 
     b = 18.2912(4) Å β= 95.3460(9)°. 
     c = 11.1855(3) Å γ = 90°. 
Volume    1726.37(7) Å3 
Z     4 
Density (calculated)   1.375 Mg/m3 
Absorption coefficient  0.103 mm-1 
F(000)     752 
Crystal size    0.31 x 0.09 x 0.08 mm 
Theta range for data collection 2.14 to 27.49°. 
Index ranges    -10<=h<=11, -23<=k<=23, -14<=l<=14 
Reflections collected   7575 
Independent reflections  3947 [R(int) = 0.0262] 
Completeness to theta = 27.49° 99.8 %  
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3947 / 0 / 312 
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Goodness-of-fit on F2   0.997 
Final R indices    [I>2sigma(I)] R1 = 0.0445, wR2 = 0.1018 
R indices (all data)   R1 = 0.0737, wR2 = 0.1162 
Extinction coefficient   6.1(11)x10-6 
Largest diff. peak and hole  0.269 and -0.241 e.Å-3 
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 Table 2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2 x 103) for nitroalkene 80b.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O1 8043(1) 4850(1) 4287(1) 32(1) 
C2 8033(2) 5636(1) 4065(1) 26(1) 
C3 6858(2) 6029(1) 4761(1) 26(1) 
C4 7076(2) 5852(1) 6108(1) 24(1) 
C5 8725(2) 6055(1) 6663(1) 27(1) 
C6 9062(2) 6565(1) 7494(2) 34(1) 
C7 7825(2) 7044(1) 7874(2) 39(1) 
C8 6309(2) 7044(1) 7049(2) 34(1) 
C9 5769(2) 6254(1) 6753(1) 26(1) 
C10 5382(2) 5842(1) 7852(1) 28(1) 
C11 5758(2) 5146(1) 8103(2) 29(1) 
C12 6535(2) 4695(1) 7269(1) 26(1) 
C13 6658(2) 3941(1) 7421(2) 29(1) 
C14 7222(2) 3509(1) 6534(1) 27(1) 
C15 7653(2) 3823(1) 5489(1) 24(1) 
C16 7557(2) 4591(1) 5339(1) 23(1) 
C17 7015(2) 5024(1) 6226(1) 23(1) 
O18 7613(1) 5737(1) 2853(1) 31(1) 
C19 8787(2) 5518(1) 2081(2) 42(1) 
C20 8453(4) 5877(2) 895(2) 73(1) 
O21 8019(2) 7422(1) 8774(2) 67(1) 
N22 4285(2) 6191(1) 8602(1) 37(1) 
O23 3398(2) 6669(1) 8140(1) 42(1) 
O24 4234(2) 5991(1) 9645(1) 64(1) 
O25 8180(1) 3456(1) 4550(1) 29(1) 
C26 8225(3) 2673(1) 4613(2) 36(1) 
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Appendix C: X-ray Data for the nitroalkane 81a. 
 
Figure 1.  View of nitroalkane 81a showing the atom labeling scheme.  Displacement 












X-ray Experimental for nitroalkane 81a 
 
Crystals grew as pale yellow plates by slow evaporation from ether.  The data 
crystal was a plate that had approximate dimensions; 0.27 x 0.14 x 0.03 mm.  The data 
were collected on a Nonius Kappa CCD diffractometer using a graphite monochromator 
with MoKα radiation (λ = 0.71073Å).  A total of 235 frames of data were collected using 
ω-scans with a scan range of 2° and a counting time of 218 seconds per frame.  The data 
were collected at 153 K using an Oxford Cryostream low temperature device.  Details of 
crystal data, data collection and structure refinement are listed in Table 1.  Data reduction 
were performed using DENZO-SMN.1  The structure was solved by direct methods using 
SIR972 and refined by full-matrix least-squares on F2 with anisotropic displacement 
parameters for the non-H atoms using SHELXL-97.3  The hydrogen atoms on carbon 


















) refined to 0.102, with R(F) equal to 
0.0386 and a goodness of fit, S, = 1.01.  Definitions used for calculating R(F), Rw(F
2
) 
and the goodness of fit, S, are given below.
4
  The data were corrected for secondary 









 where k is the overall scale factor.  Neutral atom scattering factors and 
values used to calculate the linear absorption coefficient are from the International Tables 
for X-ray Crystallography (1992).
5  All figures were generated using SHELXTL/PC.
6
  
Tables of positional and thermal parameters, bond lengths and angles, torsion angles, 
figures and lists of observed and calculated structure factors are located in tables 1 
through 7.   
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Table 1.  Crystal data and structure refinement for nitroalkane 81a. 
 
Empirical formula    C19 H21 N O6 
Formula weight    359.37 
Temperature     153(2) K 
Wavelength     0.71073 Å 
Crystal system    Triclinic 
Space group     P-1 
Unit cell dimensions   a = 8.7189(2) Å α= 106.745(1)°. 
     b = 9.8011(3) Å β= 92.890(1)°. 
     c = 11.0087(3) Å γ = 109.487(1)°. 
Volume    837.99(4) Å3 
Z     2 
Density (calculated)   1.424 Mg/m3 
Absorption coefficient  0.106 mm-1 
F(000)     380 
Crystal size    0.27 x 0.14 x 0.03 mm 
Theta range for data collection 1.96 to 27.49°. 
Index ranges    -11<=h<=11, -12<=k<=10, -14<=l<=14 
Reflections collected   6291 
Independent reflections  3820 [R(int) = 0.0185] 
Completeness to theta = 27.49° 99.4 %  
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3820 / 0 / 320 
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Goodness-of-fit on F2   1.011 
Final R indices [I>2sigma(I)]  R1 = 0.0386, wR2 = 0.0903 
R indices (all data)   R1 = 0.0578, wR2 = 0.1020 
Extinction coefficient   1.8(3)x10-5 
Largest diff. peak and hole  0.262 and -0.200 e.Å-3 
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 Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for nitroalkane 81a. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
______________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O1 787(1) 1248(1) 4421(1) 24(1) 
C2 -144(2) 2246(2) 4685(1) 22(1) 
C3 781(2) 3804(2) 5687(1) 23(1) 
C4 2114(2) 3776(1) 6644(1) 20(1) 
C5 1307(2) 2661(2) 7343(1) 23(1) 
C6 1120(2) 3062(2) 8573(1) 27(1) 
C7 1634(2) 4666(2) 9381(1) 27(1) 
C8 2025(2) 5800(2) 8655(1) 26(1) 
C9 3044(2) 5405(2) 7603(1) 22(1) 
C10 4742(2) 5520(2) 8181(1) 24(1) 
C11 5836(2) 5292(2) 7172(1) 27(1) 
C12 4971(2) 3795(2) 6111(1) 23(1) 
C13 5860(2) 3043(2) 5362(1) 27(1) 
C14 5084(2) 1690(2) 4345(1) 27(1) 
C15 3383(2) 1098(2) 4023(1) 23(1) 
C16 2475(2) 1873(2) 4750(1) 20(1) 
C17 3244(2) 3163(2) 5826(1) 20(1) 
018 -582(1) 2535(1) 3574(1) 28(1) 
C19 -1540(2) 1203(2) 2495(1) 28(1) 
C20 -518(2) 941(2) 1454(2) 36(1) 
O21 1727(1) 5044(1) 10552(1) 36(1) 
N22 5553(2) 7096(1) 9166(1) 29(1) 
O23 5690(2) 7205(1) 10303(1) 38(1) 
O24 5985(2) 8198(1) 8782(1) 51(1) 
O25 2487(1) -222(1) 3051(1) 29(1) 
C26 3391(2) -1065(2) 2328(2) 33(1) 
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Appendix D: X-ray data for the acetoxybromide 102. 
 
Figure 1.  View of acetoxybromide 102.  Displacement ellipsoids are scaled to the 50% 


















X-ray Experimental for the acetoxybromide 102 
  
Crystals grew as colorless prisms by slow evaporation from hexanes.  The data 
crystal was cut from a larger crystal and had approximate dimensions; 0.27 x 0.08 x 0.08 
mm.  The data were collected on a Rigaku R-Axis Spider diffractometer with an image 
plate detector using a graphite monochromator with CuKα radiation (λ = 1.5418Å).  A 
total of 108 images of data were collected using ω-scans with a scan range of 5° and a 
counting time of 300 seconds per image.  The data were collected at 100 K using a 
Rigaku XStream low temperature device.  Details of crystal data, data collection and 
structure refinement are listed in Table 1.  Data reduction were performed using the 
Rigaku Americas Corporation’s Crystal Clear version 1.40.1  The structure was solved by 
direct methods using SIR972 and refined by full-matrix least-squares on F2 with 
anisotropic displacement parameters for the non-H atoms using SHELXL-97.3  The 
hydrogen atoms were calculated in ideal positions with isotropic displacement parameters 
set to 1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms).  The function, 
Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + (0.0186*P)2 + (6.627*P)] and 
P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.172, with R(F) equal to 0.0702 and a goodness 
of fit, S, = 1.93.  Definitions used for calculating R(F), Rw(F2) and the goodness of fit, S, 
are given below.4  The data were checked for secondary extinction effects but no 
correction was necessary.  Neutral atom scattering factors and values used to calculate the 
linear absorption coefficient are from the International Tables for X-ray Crystallography 
(1992).5  All figures were generated using SHELXTL/PC.6  Tables of positional and 
thermal parameters, bond lengths and angles, torsion angles and figures are found 
elsewhere.   
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Table 1.  Crystal data and structure refinement for the acetoxybromide 102. 
 
Empirical formula    C25 H32 Br2 N O6 
Formula weight    602.34 
Temperature     100(2) K 
Wavelength     1.54180 Å 
Crystal system   Monoclinic 
Space group     P21/n 
Unit cell dimensions   a = 15.8880(10) Å α= 90°. 
     b = 7.2820(3) Å β= 90.706(2)°. 
     c = 21.5351(13) Å γ = 90°. 
Volume    2491.3(2) Å
3
 
Z     4 
Density (calculated)   1.606 Mg/m3 
Absorption coefficient  4.474 mm-1 
F(000)     1228 
Crystal size    0.3 x 0.2 x 0.1 mm 
Theta range for data collection 6.69 to 67.48°. 
Index ranges    -17<=h<=10, -8<=k<=8, -25<=l<=25 
Reflections collected   20964 
Independent reflections  3910 [R(int) = 0.0570] 
Completeness to theta = 67.48° 87.1 %  
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmission  0.64 and 0.35 




Data / restraints / parameters  3910 / 0 / 283 
Goodness-of-fit on F
2
   1.928 
Final R indices [I>2sigma(I)]  R1 = 0.0741, wR2 = 0.1622 
R indices (all data)   R1 = 0.0834, wR2 = 0.1702 
Largest diff. peak and hole  1.193 and -1.049 e.Å-3 
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 Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for acetoxybromide 102.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
 
______________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
Br1 -409(1) 2769(1) 4004(1) 32(1) 
Br2 4777(1) -1213(1) 3949(1) 39(1) 
O1 2731(3) -1984(6) 4365(2) 27(1) 
C2 3318(5) -601(9) 4673(3) 26(2) 
C3 2707(5) 730(10) 5015(3) 26(2) 
C4 2525(5) -21(9) 5673(3) 23(2) 
C5 1821(5) 1113(9) 5962(3) 26(2) 
N6 2001(4) 3085(7) 5927(3) 26(1) 
C7 2202(5) 3802(9) 5296(3) 25(2) 
C8 1397(5) 3677(9) 4838(3) 26(2) 
C9 1281(5) 1835(9) 4515(3) 24(2) 
C10 597(5) 1276(9) 4112(3) 29(2) 
C11 584(5) -409(9) 3786(3) 24(2) 
C12 1283(5) -1596(9) 3840(3) 26(2) 
C13 1960(5) -1047(9) 4246(3) 26(2) 
C14 3795(4) 319(9) 4150(3) 24(2) 
C15 4106(5) 2256(10) 4314(3) 25(2) 
C16 3353(5) 3477(10) 4468(3) 28(2) 
C17 2982(5) 2760(9) 5083(3) 23(2) 
C18 1929(5) 569(9) 4580(3) 24(2) 
C19 2088(5) 4243(9) 6434(3) 23(2) 
O20 2266(3) 5840(6) 6407(2) 28(1) 
O21 1891(3) 3356(6) 6976(2) 27(1) 
C22 2074(5) 4437(9) 7554(3) 28(2) 
C23 1344(5) 5702(10) 7686(3) 33(2) 
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O24 1348(3) -3231(6) 3529(2) 26(1) 
C25 661(5) -3684(10) 3081(4) 35(2) 
O26 4493(3) 2989(7) 3761(2) 29(1) 
C27 5281(5) 3760(9) 3859(4) 27(2) 
O28 5670(4) 3879(7) 4365(2) 39(1) 






















Appendix E: X-ray data for the β-hydroxyketone 132a. 
 
Figure 1.  View of β-hydroxyketone 132a.  Displacement ellipsoids are scaled to the 50% 













X-ray Experimental for β-hydroxyketone 132a 
 
Crystals grew as colorless laths by slow evaporation from methanol. The data 
crystal was cut from a larger crystal and had approximate dimensions; 0.12 x 0.02 x 0.02 
mm.  The data were collected on a Rigaku R-Axis Spider diffractometer with an image 
plate detector using a graphite monochromator with CuKα radiation (λ = 1.5418Å).  A 
total of 144 images of data were collected using ω-scans with a scan range of 5° and a 
counting time of 450 seconds per image.  The data were collected at 100 K using a 
Rigaku XStream low temperature device.  Details of crystal data, data collection and 
structure refinement are listed in Table 1.  Data reduction were performed using the 
Rigaku Americas Corporation’s Crystal Clear version 1.40.1  The structure was solved by 
direct methods using SIR972 and refined by full-matrix least-squares on F2 with 
anisotropic displacement parameters for the non-H atoms using SHELXL-97.3  The 
hydrogen atoms were calculated in ideal positions with isotropic displacement parameters 
set to 1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms).  The function, 
Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + (0.03*P)2] and P = (|Fo|2 + 
2|Fc|2)/3.  Rw(F2) refined to 0.214, with R(F) equal to 0.148 and a goodness of fit, S, = 
1.75.  Definitions used for calculating R(F), Rw(F2) and the goodness of fit, S, are given 
below.4  The data were checked for secondary extinction effects but no correction was 
necessary.  Neutral atom scattering factors and values used to calculate the linear 
absorption coefficient are from the International Tables for X-ray Crystallography 
(1992).5  All figures were generated using SHELXTL/PC.6  Tables of positional and 
thermal parameters, bond lengths and angles, torsion angles and figures are found 
elsewhere.   
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Table 1.  Crystal data and structure refinement for β-hydroxyketone 132a. 
 
Identification code    shelxl 
Empirical formula    C18 H23 B N2 O4 
Formula weight    342.19 
Temperature     100(2) K 
Wavelength     1.54187 Å 
Crystal system    Monoclinic 
Space group     P21/c 
Unit cell dimensions   a = 27.2222(4) Å α= 90°. 
     b = 6.6121(1) Å β= 105.697(1)°. 
     c = 19.9706(5) Å γ = 90°. 
Volume    3460.57(11) Å3 
Z     8 
Density (calculated)   1.314 Mg/m3 
Absorption coefficient  0.748 mm-1 
F(000)     1456 
Crystal size    0.12 x 0.02 x 0.02 mm3 
Theta range for data collection 6.91 to 67.49°. 
Index ranges    -32<=h<=28, -7<=k<=7, -23<=l<=23 
Reflections collected   29423 
Independent reflections  6137 [R(int) = 0.1265] 
Completeness to theta = 67.49° 98.5 %  
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmission  0.99 and 0.82 
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Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  6137 / 0 / 458 
Goodness-of-fit on F2   1.753 
Final R indices [I>2sigma(I)]  R1 = 0.1482, wR2 = 0.1543 
R indices (all data)   R1 = 0.2992, wR2 = 0.2138 
Extinction coefficient   0.00167(17) 
Largest diff. peak and hole  0.601 and -0.565 e.Å-3 
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 Table 2.  Atomic coordinates ( x 10
4





) for β-hydroxyketone 102a.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O1A 8589(2) 5565(7) 4376(2) 49(2) 
O2A 8455(2) 3280(7) 2618(3) 58(2) 
O3A 9232(2) -220(8) 4089(2) 51(2) 
O4A 7812(2) 7433(8) 4778(2) 51(2) 
N1A 9027(2) -3448(9) 7684(3) 55(2) 
B1A 9381(3) -2540(13) 6577(5) 54(3) 
C1A 9054(3) 4366(12) 4418(4) 51(2) 
C2A 9079(3) 4165(11) 3673(4) 54(2) 
C3A 8629(3) 2976(12) 3233(5) 52(3) 
C4A 8421(3) 1429(10) 3629(4) 45(2) 
C5A 8802(3) 665(12) 4288(4) 53(2) 
C6A 9009(3) 2378(12) 4805(4) 41(2) 
C7A 9519(3) 1898(10) 5312(3) 43(2) 
C8A 9531(3) -108(11) 5698(3) 54(2) 
N9A 9250(2) -268(9) 6265(3) 46(2) 
C10A 8676(3) -30(11) 5988(3) 46(2) 
C11A 8475(3) 2013(11) 5706(4) 38(2) 
C12A 8101(3) 2953(12) 5945(4) 47(2) 
C13A 7863(3) 4777(12) 5656(4) 49(2) 
C14A 8005(3) 5699(13) 5102(4) 48(2) 
C15A 8393(3) 4755(11) 4887(4) 37(2) 
C16A 8607(3) 2971(11) 5160(4) 32(2) 
C17A 9149(3) -2944(12) 7211(4) 46(2) 
C18A 9455(2) 1277(10) 6816(3) 58(2) 
C19A 7419(3) 8416(10) 5008(3) 61(2) 
O1 6476(2) -551(7) 5618(3) 46(2) 
O2 6513(2) 1156(7) 3801(3) 55(2) 
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O3 5768(2) 4928(7) 4619(2) 48(2) 
O4 7278(2) -2039(8) 6673(2) 52(2) 
N1 5924(2) 8768(9) 8345(3) 56(2) 
B1 5574(3) 7767(13) 6966(4) 58(3) 
C1 5996(3) 457(11) 5263(4) 45(2) 
C2 5942(3) 387(11) 4488(4) 51(2) 
C3 6364(3) 1584(13) 4305(4) 55(3) 
C4 6588(3) 3288(11) 4781(3) 45(2) 
C5 6205(3) 4186(11) 5139(4) 48(2) 
C6 6034(3) 2597(11) 5592(4) 35(2) 
C7 5510(3) 3137(10) 5704(3) 43(2) 
C8 5468(2) 5180(11) 6021(3) 46(2) 
N9 5738(2) 5517(9) 6780(3) 44(2) 
C10 6323(3) 5477(11) 6925(3) 52(2) 
C11 6559(3) 3428(12) 6864(4) 41(2) 
C12 6947(3) 2719(12) 7426(4) 44(2) 
C13 7191(3) 896(12) 7379(4) 51(2) 
C14 7064(3) -192(13) 6778(5) 48(2) 
C15 6661(3) 469(15) 6224(4) 50(3) 
C16 6431(3) 2309(12) 6274(4) 41(2) 
C17 5797(3) 8274(11) 7771(5) 48(2) 
C18 5586(2) 3984(10) 7236(3) 53(2) 










Appendix F: X-ray data for the nitroalcohol 114a. 
 
Figure 1.  View of nitroalcohol 114a showing the atom labeling scheme. Displacement 
















X-ray Experimental for nitroalcohol 114a:  
 
Crystals grew as colorless prisms by slow evaporation from toluene.  The data 
crystal was cut from a larger crystal and had approximate dimensions; 0.22 x 0.22 x 0.12 
mm.  The data were collected on a Nonius Kappa CCD diffractometer using a graphite 
monochromator with MoKα radiation (λ = 0.71073Å).  A total of 184 frames of data 
were collected using ω-scans with a scan range of 1.8° and a counting time of 66 seconds 
per frame.  The data were collected at 153 K using an Oxford Cryostream low 
temperature device.  Details of crystal data, data collection and structure refinement are 
listed in Table 1.  Data reduction were performed using DENZO-SMN.1  The structure 
was solved by direct methods using SIR972 and refined by full-matrix least-squares on F2 
with anisotropic displacement parameters for the non-H atoms using SHELXL-97.3  The 
hydrogen atoms on carbon were calculated in ideal positions with isotropic displacement 
parameters set to 1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms).  
The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + (0.0596*P)2 + 
(1.1616*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.161, with R(F) equal to 
0.0653 and a goodness of fit, S, = 1.04.  Definitions used for calculating R(F), Rw(F2) 
and the goodness of fit, S, are given below.4  The data were checked for secondary 
extinction effects but no correction was necessary.  Neutral atom scattering factors and 
values used to calculate the linear absorption coefficient are from the International Tables 
for X-ray Crystallography (1992).5  All figures were generated using SHELXTL/PC.6  
Tables of positional and thermal parameters, bond lengths and angles, torsion angles, 
figures and lists of observed and calculated structure factors are located in tables 1 
through 7.   
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Table 1.  Crystal data and structure refinement for nitroalcohol 114a. 
 
Empirical formula    C19 H21 N O7 
Formula weight    375.37 
Temperature     153(2) K 
Wavelength     0.71070 Å 
Crystal system    Monoclinic 
Space group     P21/c 
Unit cell dimensions   a = 11.3843(6) Å α= 90°. 
     b = 17.2041(11) Å β= 102.762(2)°. 
     c = 9.1689(8) Å γ = 90°. 
Volume    1751.4(2) Å3 
Z     4 
Density (calculated)   1.424 Mg/m3 
Absorption coefficient  0.109 mm-1 
F(000)     792 
Crystal size    0.22 x 0.22 x 0.12 mm 
Theta range for data collection 1.83 to 27.47°. 
Index ranges    -14<=h<=14, -22<=k<=17, -11<=l<=11 
Reflections collected   6616 
Independent reflections  3990 [R(int) = 0.0339] 
Completeness to theta = 27.47° 99.6 %  
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3990 / 0 / 247 
Goodness-of-fit on F2   1.036 
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Final R indices [I>2sigma(I)]  R1 = 0.0653, wR2 = 0.1354 
R indices (all data)   R1 = 0.1283, wR2 = 0.1606 
Largest diff. peak and hole  0.594 and -0.296 e.Å-3 
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 Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for nitroalcohol 114a. U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
 
______________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O1 5348(2) 1216(1) 3823(2) 32(1) 
C2 4795(2) 1392(1) 4970(3) 27(1) 
C3 5519(2) 1776(1) 6201(3) 30(1) 
C4 5041(3) 1954(2) 7422(3) 34(1) 
C5 3860(3) 1758(2) 7431(3) 35(1) 
C6 3137(2) 1400(1) 6207(3) 29(1) 
C7 1862(2) 1168(2) 6166(3) 36(1) 
C8 1013(2) 1376(2) 4664(3) 35(1) 
C9 1548(2) 1326(1) 3260(3) 27(1) 
C10 645(2) 945(1) 1968(3) 30(1) 
C11 471(2) 93(2) 2228(3) 30(1) 
C12 1481(2) -324(1) 3168(3) 33(1) 
C13 2519(2) 21(2) 3776(3) 32(1) 
C14 2766(2) 879(1) 3572(3) 27(1) 
C15 3377(2) 986(2) 2238(3) 30(1) 
C16 4673(2) 737(2) 2631(3) 30(1) 
C17 3601(2) 1219(1) 4951(3) 27(1) 
O18 5180(2) 849(1) 1409(2) 32(1) 
C19 6340(2) 484(2) 1538(3) 35(1) 
C20 6856(2) 771(2) 272(3) 39(1) 
O21 6660(2) 1947(1) 6059(2) 38(1) 
C22 7432(3) 2320(2) 7307(3) 43(1) 
O23 1445(2) 1530(1) 7361(2) 50(1) 
N24 620(3) 2210(2) 4854(3) 51(1) 
O25 1389(2) 2718(1) 5005(2) 61(1) 
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O26 -436(2) 2304(2) 4893(3) 97(1) 












































Appendix G: X-ray data for the nitroalcohol 114b. 
 
 
Figure 1.  View of nitroalcohol 114b showing the atom labeling scheme.  Displacement 













X-ray Experimental for the nitroalcohol 114b 
 
Crystals grew as colorless prisms by slow evaporation from toluene. The data 
crystal was cut from a cluster of crystals and had approximate dimensions; 0.21 x 0.12 x 
0.11 mm.  The data were collected on a Nonius Kappa CCD diffractometer using a 
graphite monochromator with MoKα radiation (λ = 0.71073Å).  A total of 146 frames of 
data were collected using ω-scans with a scan range of 2° and a counting time of 138 
seconds per frame.  The data were collected at 153 K using an Oxford Cryostream low 
temperature device.  Details of crystal data, data collection and structure refinement are 
listed in Table 1.  Data reduction were performed using DENZO-SMN.1  The structure 
was solved by direct methods using SIR972 and refined by full-matrix least-squares on F2 
with anisotropic displacement parameters for the non-H atoms using SHELXL-97.3  The 
hydrogen atoms on carbon were calculated in ideal positions with isotropic displacement 
parameters set to 1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms).  
The hydrogen atom bound to O25 was observed in a ∆F map and refined with an 
isotropic displacement parameter.  The function, Σw(|Fo|
2 - |Fc|
2)2, was minimized, where 
w = 1/[(σ(Fo))2 + (0.0486*P)2 + (0.4664*P)] and P = (|Fo|
2 + 2|Fc|
2)/3.  Rw(F
2) refined to 
0.129, with R(F) equal to 0.0558 and a goodness of fit, S = 1.02.  Definitions used for 
calculating R(F), Rw(F
2) and the goodness of fit, S, are given below.4  The data were 
checked for secondary extinction but no correction was necessary. Neutral atom 
scattering factors and values used to calculate the linear absorption coefficient are from 
the International Tables for X-ray Crystallography (1992).5  All figures were generated 
using SHELXTL/PC.6  Tables of positional and thermal parameters, bond lengths and 
angles, torsion angles, figures and lists of observed and calculated structure factors are 
located in tables 1 through 7.   
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Table 1.  Crystal data and structure refinement for nitroalcohol 114b. 
 
Empirical formula    C19 H21 N O7 
Formula weight    375.37 
Temperature     153(2) K 
Wavelength     0.71070 Å 
Crystal system    Monoclinic 
Space group     P21/n 
Unit cell dimensions   a = 14.7812(8) Å α= 90°. 
     b = 7.9289(6) Å β= 116.551(4)°. 
     c = 16.4024(12) Å γ = 90°. 
Volume    1719.6(2) Å3 
Z     4 
Density (calculated)   1.450 Mg/m3 
Absorption coefficient  0.111 mm-1 
F(000)     792 
Crystal size    0.20 x 0.12 x 0.11 mm 
Theta range for data collection 2.92 to 27.37°. 
Index ranges    -19<=h<=19, -10<=k<=9, -21<=l<=21 
Reflections collected   6592 
Independent reflections  3884 [R(int) = 0.0601] 
Completeness to theta = 27.37° 99.4 %  
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3884 / 0 / 250 
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Goodness-of-fit on F2   1.022 
Final R indices [I>2sigma(I)]  R1 = 0.0558, wR2 = 0.1090 
R indices (all data)   R1 = 0.1151, wR2 = 0.1286 
Largest diff. peak and hole  0.264 and -0.269 e.Å-3 
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 Table 2.  Atomic coordinates ( x 10
4





) for nitroalcohol 114b. U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
_______________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O1 5535(1) 1950(2) 2876(1) 26(1) 
C2 5461(2) 2397(3) 3691(2) 26(1) 
C3 4626(2) 3669(3) 3476(2) 25(1) 
C4 4810(2) 5338(3) 3077(1) 21(1) 
C5 5475(2) 6470(3) 3860(1) 24(1) 
C6 5126(2) 7702(3) 4198(2) 26(1) 
C7 4039(2) 8128(3) 3809(2) 27(1) 
C8 3335(2) 6895(3) 3123(2) 27(1) 
C9 3793(2) 6261(3) 2507(1) 22(1) 
C10 3923(2) 7780(3) 1972(1) 23(1) 
C11 4929(2) 7898(3) 1920(2) 25(1) 
C12 5329(2) 6174(3) 1861(2) 23(1) 
C13 5732(2) 5819(3) 1264(2) 29(1) 
C14 6092(2) 4215(3) 1230(2) 29(1) 
C15 6036(2) 2969(3) 1787(2) 24(1) 
C16 5619(2) 3303(3) 2388(1) 22(1) 
C17 5282(1) 4920(3) 2442(1) 20(1) 
O18 6374(1) 3051(2) 4341(1) 27(1) 
C19 7190(2) 1847(3) 4593(2) 32(1) 
C20 8109(2) 2506(3) 5396(2) 36(1) 
O21 3736(1) 9410(2) 4015(1) 38(1) 
N22 3066(1) 7700(2) 1018(1) 29(1) 
O23 3119(1) 6701(2) 476(1) 38(1) 
O24 2344(1) 8630(2) 848(1) 54(1) 
O25 4806(1) 8966(2) 1187(1) 34(1) 
O26 6356(1) 1322(2) 1807(1) 31(1) 
C27 6942(2) 974(3) 1327(2) 43(1) 
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Appendix H: X-ray data for the nitroether 116. 
 
 
Figure 1.  View of nitroether 116 showing the atom labeling scheme.  Displacement 















X-ray Experimental for nitroether 116. 
 
Crystals grew as colorless plates by slow evaporation from chloroform.  The data 
crystal was cut from a larger crystal and had approximate dimensions; 0.33 x 0.30 x 0.05 
mm.  The data were collected on a Nonius Kappa CCD diffractometer using a graphite 
monochromator with MoKα radiation (λ = 0.71073Å).  A total of 99 frames of data were 
collected using ω-scans with a scan range of 2° and a counting time of 154 seconds per 
frame.  The data were collected at 153 K using an Oxford Cryostream low temperature 
device.  Details of crystal data, data collection and structure refinement are listed in Table 
1.  Data reduction were performed using DENZO-SMN.1  The structure was solved by 
direct methods using SIR972 and refined by full-matrix least-squares on F2 with 
anisotropic displacement parameters for the non-H atoms using SHELXL-97.3  The 
hydrogen atoms on carbon were calculated in ideal positions with isotropic displacement 
parameters set to 1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms).  
The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + (0.0608*P)2 + 
(13.1411*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.152, with R(F) equal to 
0.0567 and a goodness of fit, S, = 0.990.  Definitions used for calculating R(F), Rw(F2) 
and the goodness of fit, S, are given below.4  The data were checked for secondary 
extinction but no correction was necessary.  Neutral atom scattering factors and values 
used to calculate the linear absorption coefficient are from the International Tables for X-
ray Crystallography (1992).5  All figures were generated using SHELXTL/PC.6  Tables 
of positional and thermal parameters, bond lengths and angles, torsion angles, figures and 




  Table 1.  Crystal data and structure refinement for nitroether 116. 
 
Empirical formula    C20.50 H22.50 Cl4.50 N O7 
Formula weight    554.42 
Temperature     153(2) K 
Wavelength     0.71070 Å 
Crystal system    Monoclinic 
Space group     C2/c 
Unit cell dimensions   a = 27.5026(15) Å α= 90°. 
     b = 12.6167(8) Å β= 114.238(2)°. 
     c = 15.2499(12) Å γ = 90°. 
Volume    4825.1(6) Å3 
Z     8 
Density (calculated)   1.526 Mg/m3 
Absorption coefficient  0.588 mm-1 
F(000)     2280 
Crystal size    0.33 x 0.30 x 0.05 mm 
Theta range for data collection 2.11 to 27.47°. 
Index ranges    -35<=h<=35, -16<=k<=14, -19<=l<=19 
Reflections collected   9042 
Independent reflections  5429 [R(int) = 0.0318] 
Completeness to theta = 27.47° 98.2 %  
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmission  0.97 and 0.82 
Refinement method   Full-matrix least-squares on F2 
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Data / restraints / parameters  5429 / 30 / 318 
Goodness-of-fit on F2   0.982 
Final R indices [I>2sigma(I)]  R1 = 0.0567, wR2 = 0.1312 
R indices (all data)   R1 = 0.0937, wR2 = 0.1525 
Largest diff. peak and hole  0.774 and -0.626 e.Å-3 
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 Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for nitroether 116. U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
 
______________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
Cl1A 866(1) 7546(1) 3052(1) 67(1) 
Cl2A 387(1) 7039(1) 4348(1) 74(1) 
Cl3A 487(1) 9222(1) 3888(1) 105(1) 
C1A 781(1) 7975(3) 4070(3) 52(1) 
Cl1B -372(1) 4687(2) 3594(2) 85(1) 
Cl2B -527(3) 4193(5) 1673(3) 65(1) 
Cl3B 537(2) 4415(6) 3118(5) 107(2) 
C1B -117(3) 4855(5) 2727(5) 51(2) 
O1 3218(1) 2656(1) 5882(1) 25(1) 
C2 3120(1) 3049(2) 6684(2) 23(1) 
C3 2612(1) 3701(2) 6346(2) 22(1) 
C4 2617(1) 4646(2) 5713(2) 20(1) 
C5 2850(1) 5687(2) 6271(2) 21(1) 
C6 2522(1) 6125(2) 6792(2) 25(1) 
C7 1943(1) 6249(2) 6124(2) 23(1) 
C8 1696(1) 5305(2) 5486(2) 23(1) 
C9 2045(1) 4930(2) 4968(2) 21(1) 
C10 2087(1) 5809(2) 4300(2) 21(1) 
C11 2674(1) 6136(2) 4614(2) 22(1) 
C12 2992(1) 5190(2) 4582(2) 21(1) 
C13 3300(1) 5054(2) 4066(2) 25(1) 
C14 3567(1) 4099(2) 4139(2) 26(1) 
C15 3539(1) 3296(2) 4742(2) 24(1) 
C16 3229(1) 3451(2) 5271(2) 21(1) 
C17 2955(1) 4382(2) 5176(2) 20(1) 
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O18 2841(1) 6506(1) 5589(1) 24(1) 
O19 3545(1) 3685(1) 7275(1) 25(1) 
C20 4042(1) 3117(3) 7710(2) 38(1) 
C21 4460(1) 3872(3) 8328(3) 60(1) 
O22 1696(1) 7057(1) 6085(1) 29(1) 
N23 1876(1) 5479(2) 3251(2) 24(1) 
O24 1754(1) 4566(2) 3015(2) 44(1) 
O25 1861(1) 6178(2) 2684(1) 37(1) 
O26 3789(1) 2334(2) 4877(1) 30(1) 
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List of Abbreviations 
 
Å     ångström unit 
Ac      acetyl  
AIBN      2,2’-azobisisobutyronitrile  
Ar      aryl  
atm      atmosphere  
BHT      butylated hydroxytoluene  
Bn      benzyl  
bs      broad singlet 
Bu      butyl  
c     concentration 
cat.      catalytic  
CI      chemical ionization 
Cy     cyclohexyl  
m-CPBA     meta-chloroperoxybenzoic acid  
d      doublet  
D     Sodium D-line; 589 nanometers 
DBH     3,5-dibromo-5,5-dimethylhydantoin 
DBN     1,5-Diazabicyclo(4.3.0)non-5-ene 
DBU      1,8-diazabicyclo[5.4.0]undec-7-ene 
DCE      1,2-dichloroethane  
DCM      dichloromethane  
dd      double of doublets  
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DDQ      2,3-dichloro-5,6-dicyano-1,4-benzoquinone  
DIPEA     N,N-diisopropylethylamine 
Dioxane    1,4-dioxane 
DME     1,4-dimethoxyethane 
DMF      N,N-dimethylformamide  
DMP      Dess-Martin periodinane  
DMSO     dimethylsulfoxide  
dt     doublet of triplets 
ee     enantiomeric excess 
equiv.      equivalents  
Et      ethyl  
g     gram 
h     hour 
[H]     reduction 
HPLC     high pressure liquid chromatography 
HRMS     high resolution mass spectrometry  
imid.      imidazole  
IR      infrared  
LAH      lithium aluminum hydride  
m      multiplet  
m      meta  
M      molar  
Me      methyl  
mM      millimole  
min     minute 
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MOM      methoxymethyl  
mp      melting point  
Ms      methanesulfonyl  
MS      mass spectrometry 
MsOH     methanesulfonic acid  
NBS     N-bromosuccinimide 
NCS      N-chlorosuccinimide 
nm     nanometer  
NMR      nuclear magnetic resonance  
o      ortho  
[O]     oxidation 
ORTEP     Oak Ridge thermal ellipsoid program 
p      para  
PCC      pyridinium chlorochromate  
Ph      phenyl  
ppm      parts per million  
Pr      propyl  
prep     preparative 
pyr.      pyridine  
R      generic functional group  
q      quartet 
qd     quadruplet of doublets  
s      singlet  
t      triplet  
TBAF                tetrabutylammonium fluoride  
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TBDPS     tert-butyldiphenylsilyl  
TBDS or TBDMS    tert-butyldimethylsilyl  
TEA      triethylamine 
Td     triplet of doublets  
TFA      trifluoroacetic acid  
TFAA      trifluoroacetic anhydride  
THF      tetrahydrofuran  
TIPS      triisopropylsilyl  
TIPSOTf    triisopropyl trifluoromethanesulfonate 
TLC      thin layer chromatography  
TMS      trimethylsilyl  
TMSOTf     trimethylsilyl trifluoromethanesulfonate  
Ts      toluenesulfonyl  
TsOH or pTSA    toluenesulfonic acid 
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